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Abstract 
 
Syndecan-4 (SDC-4), a transmembrane heparan sulphate proteoglycan and a co-
receptor of integrins for fibronectin, has been reported to modulate the adhesion of cells 
to a range of extracellular matrix ligands. In addition to the modulation of integrins, 
SDC-4 has been recently reported to modify the interaction of some growth factors with 
their receptors. 
T cells are essential effectors of the adaptive immune response. When conjugating with 
antigen-presenting cells (APCs), T cells transform their shape to enable formation of a 
specialised morphological structure, called the immunological synapse (IS). The IS 
formation is associated with the polarisation of signalling and adhesive molecules 
towards the APC. The IS is formed and stabilized by similar adhesive forces and 
structures as in the motile fibroblasts - an extensively studied model of syndecan 
function. 
In this thesis I have investigated the role of SDC-4 in T cell - APC recognition and the 
IS. First, I confirmed the tight regulation of SDC-4 expression in T cells during the 
process of activation. Flow cytometry and PCR data demonstrate increased presence of 
SDC-4 in stimulated human T cells compared to their resting counterparts, indicating 
involvement of SDC-4 in the processes of T cell activation. Transient transfection of 
exogenous SDC-4 into Jurkat T cells with low endogenous SDC-4 expression was used 
as a model to study the effect of increased SDC-4 expression on T cell function.  
Using live cell imaging and advanced data image analysis I have quantitatively 
demonstrated that SDC-4 transfected Jurkat T cells are less likely to modify their shape 
during IS formation when compared to mock transfected Jurkat T cells. I also observed 
a delay in T cell antigenic response caused by SDC-4 over-expression. Moreover, I was 
able to visualise the exogenous SDC-4 in the IS using confocal microscopy and 
demonstrate the independence of this phenomenon on T cell receptor. 
In summary, my observations indicate a regulatory role for SDC-4 in T cell adhesion 
causing delays in the IS formation and reduced transformation of T cell shape during 
conjugate formation. 
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1 Introduction 
 
Cells are the smallest functional units of living 
organisms. One of the abilities of cells is to adhere to 
each other and to the surrounding extracellular 
matrix (ECM) [1]. Such ability is essential for the 
existence of multicellular organisms. Moreover, 
adhesion provides physical support for cells, 
regulates their positioning and enables 
microenvironmental sensing. Aberrations in cell-to-
cell or cell – ECM interactions and ECM organisation 
contribute widely to diseases, demonstrating the 
essential role of the adhesive forces and ECM in cellular function.  
Many cell-surface receptors that mediate cell-to-cell and cell – ECM adhesions are members of 
two protein gene families — integrins [2] and syndecans [3]. Intriguingly, nearly all ECM 
molecules contain binding sites for both types of receptor [1] and there is substantial evidence 
that a full cellular adhesive function requires engagement of both types of receptors. 
Intracellularly, integrins and syndecans are required to generate a physical link with the 
cytoskeleton [4], for force transduction, spatial control of the assembly of the adhesion signalling 
complex (via adhesion contacts) [5] and regulation of the cytoskeletal dynamics [6]. 
 
For a long time, the studies in this field were focused on integrins. Integrins are a large family of 
surface receptors dominating the research of adhesion and cell motility, and with which several 
proteoglycans are known to associate  [7]. One of these is syndecan-4 (SDC-4). Thus, 
observation of increased SDC-4 expression in activated compared to resting T cells brought us 
to the question: what is the function of this molecule in T cells during their activation? Is 
adhesion influenced by increased expression of SDC-4? As SDC-4 sits in the centre of my 
work, first, this family of small proteoglycans will be described in the following sections with a 
special attention towards SDC-4. 
  
Extracellular matrix (ECM) 
The extracellular matrix (ECM) is 
a specialised non-cellular 
structure primarily made of 
proteins and proteoglycans, 
which fills the large space 
between the cells, which form 
contacts with each other in 
tissues forming multicellular 
organisms. 
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1.1 Proteoglycans  
Proteoglycans (PGs) [8] can be classified into three main groups according to their localisation: 
secreted, surface associated and intracellular proteins. Each main group is further classified into 
subfamilies according to their gene homology, core protein properties, size and modular 
composition. Secreted PGs involve large aggregating PGs, named hyalectans, small leucine-
rich PGs and basement membrane PGs. Cell-surface-associated PGs are divided into two main 
subfamilies (syndecans and glypicans), whereas serglycin is the only intracellular PG 
characterised to date [9, 10]. The wide molecular diversity of PGs derives from the multitude of 
possible combinations of protein cores, O-linked and N-linked oligosaccharides, and various 
types and numbers of glycosaminoglycan (GAG) chains. The specific structural characteristics 
of GAG types provide some of the structural basis for the multitude of their biological functions 
[11]. PGs may carry heparan sulfate (HS) and/or chondroitin sulfate (CS) or dermatan sulphate 
chains linked to their extracellular domain and were first described around 30 years ago [12]. 
 
Let me focus only on the cell-surface PGs, which include two major subfamilies: the syndecans 
[13-15], with four members cloned in mammals, and are type I transmembrane proteins mostly 
substituted with HS chains; and glypicans linked to the cell membrane by a glycosyl-
phosphatidylinositol anchor, with six members cloned in mammals substituted with HS chains. 
 
 
1.2 Glypicans 
Glypicans show cell-type and developmental-stage-specific expression. They are involved in 
biological processes such as cell–ECM interactions and the control of cellular division, 
differentiation and morphogenesis [16]. At the level of signalling, they are involved in the 
regulation of pathways including fibroblast growth factor (FGF), hedgehog (Hh), bone 
morphogenic protein and insulin-like growth factor [16]. Therefore, depending on the biological 
context, glypicans can either stimulate or inhibit signalling activity. Notably, the HS chains are 
essential for the glypican-induced stimulation of FGF activity and partially required for the 
regulatory activity of glypicans in e.g. Hh and bone morphogenetic protein signalling [16]. 
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1.3 Syndecans  
Syndecans (SDCs) belong to a small group of transmembrane proteins which have GAG chains 
attached to the extracellular domain and belong to the family of PGs (Figure 1.1) [14, 15, 17].  
 
 
Figure 1.1. Transmembrane proteoglycans. Four syndecans in the centre have heparan 
sulphate chains (blue) covalently attached to their N-terminal extracellular domain. In addition, 
proteoglycans frequently possess additional chondroitin sulphate chains (pink), e.g. syndecan-1 
or CD44. Neuropilin-1 and betaglycan have dermatan sulphate chains instead (violet). Figure 
taken from Couchman et al. Annu. Rev. Cell Dev. Biol.  2010 [17]. 
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Initially, a role for heparan sulphate proteoglycans 
(HSPGs) in adhesion was proposed [1]. Of note, this 
happened before the description of integrins. For two 
decades now it has been believed that focal adhesion 
(FA) formation during cell spreading on fibronectin 
depends on the engagement of an integrin and a cell-
surface PG, specifically, α5β1 integrin and SDC-4 [18] 
(see SDC-4 section for more information).  
 
 
 
 
Syndecans act as receptors for ECM proteins and for growth factors [15], engaging ligands 
through their large flexible GAG chains that make them ideal receptors for ligands that are dilute 
or distant from the membrane. The necessity of GAG chains is demonstrated by the fact that 
cellular responses to ligands such as fibronectin [19] , fibroblast growth factor-2 (FGF2) and 
vascular endothelial growth factor (VEGF) are inhibited when the interactions of the sugar 
chains are compromised by addition of soluble competitors or disruption of the GAG 
biosynthetic machinery  [19, 20] 
Adhesion to the ECM regulates numerous signalling pathways [21]. Therefore, the ability of 
syndecans to be involved in the adhesion as well as in signalling processes brought the concept 
of syndecans as co-receptors. 
 
  
Focal adhesions (FAs) 
Focal adhesions (FAs) are highly 
dynamic, multi-protein 
complexes, through which cells 
interact with ECM (e.g. via 
integrin receptors). These large 
assemblies, which can measure 
several micrometers in diameter, 
in general mediate interactions of 
cells with external surfaces, and 
are linked at their cytoplasmic 
side with actin bundles. 
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1.3.1 Basal expression of syndecans in eukaryotic cells 
Syndecans are found in all mammalian cells. Whereas invertebrates express only a single 
syndecan, four genes (syndecans 1 to 4) encode syndecan proteins in vertebrates. Three out of 
four vertebrate syndecans (abbreviated SDC-1 to -4 subsequently) have a tissue-specific 
expression profiles [3, 22]. 
 SDC-1 is expressed predominantly in epithelial cells and is thought to play an important 
role in maintaining epithelial phenotype and morphology. It is down-regulated in several 
types of carcinoma [23]. 
 SDC-2 was originally identified in the endothelium and lung fibroblasts, but is also highly 
expressed in mesenchymal tissues surrounding blood vessels, in organs such as kidney, 
lung, liver and stomach, and in cells forming cartilage and bones [13, 24]. 
 SDC-3 is enriched in neural tissues, but also in the developing musculoskeletal system. 
This syndecan has not been proven to be involved in interactions with the ECM [25]. 
 In contrast to the previous syndecans, SDC-4 is found in virtually every cell type [26], but 
its expression level differs between the cell types and the stage of their development. 
Many cells express more than one type of syndecan, and they may possess other 
transmembrane proteoglycans as well. 
1.3.2 Regulation of syndecan expression 
In general, the expression profiles of all members of the syndecan family change in time and 
space (e.g. during tissue formation), but every mammalian cell express at least one syndecan 
type at the certain stage of its development [13]. Syndecan levels are tightly regulated as they 
are involved in tuning numerous signalling events. It has previously been shown that various 
growth factors play an important role in regulation of syndecan expression: e.g. tumour necrosis 
factor-α (TNF-α) upregulates SDC-2 and downregulates SDC-1 in endothelial cells [27]. 
Similarly, transforming growth factor–β2 (TGF-ß2) upregulates SDC-4 and downregulates SDC-
1 in epithelial cells [28] and FGF2 induces SDC-4 but not SDC-1 or SDC-2 expression in aortic 
smooth muscle cells [29]. Therefore, it is important to understand why expression levels of 
syndecans are tightly regulated by a number of factors depending on cell type. Interestingly, the 
same factors are responsible not only for a certain effect e.g. upregulation of one type of 
syndecan, but simultaneously for the downregulation of the other one in cells. 
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1.3.3 The domain structure of syndecans 
Structurally, syndecans are composed of an extracellular domain (48 amino acids) containing 
several consensus sequences for three to five HS (and/or CS chains in mouse) (Figure 
1.2).glycosaminoglycan (GAG) attachment; a single transmembrane domain (25 amino acids); 
and a C-terminal cytoplasmic domain (34 amino acids). The extracellular domain of syndecan 
interacts with a number of soluble and insoluble factors in the extracellular matrix (ECM). These 
interactions, mediated by both polysaccharide and protein components, activate syndecans to 
regulate transmembrane signaling events [30-32].  
 
Figure 1.2. General structure of syndecans. Extracellular domain contains attachment sites for 
HS (blue) and/or CS (green) chains. CS chains are attached only to murine SDCs. 
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1.3.3.1 Extracellular domain and GAG chains 
A wide array of extracellular ligands interact with heparin and HS [21] including growth factors, 
chemokines [33], lipid-regulating enzymes, ECM proteins [34], cell-cell adhesion molecules and 
blood-coagulation factors [35]. These molecules have one or more discrete domains that have 
heparin-binding characteristics and, in general, these have been demonstrated also to bind to 
the less sulphated HS, which forms distinct domains of GAG chains covalently attached to 
extracellular part of syndecans [21, 36, 37] (Figure 1.3). 
 
 
 
Figure 1.3. An example of the chondroitin (top scheme), and heparan (lower scheme) 
glycosaminoglycan chain structures. All share a common stem sequence of four sugar residues; 
are highly sulfated and substituted on serine residues. These have an adjacent glycine residue 
on the carboxy-terminal side and usually lie within an area rich in acidic residues of the 
syndecan extracellular domain (modified from Couchman et al. Annu. Rev. Cell Dev. Biol.  2010 
[17]). 
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The structural variation of HS and CS chains (Figure 1.3) results from a series of post-
translational modifications delivered by a number of enzymes, such as N-acetylglucosamine 
transferase [38]. It has been previously assumed that all syndecan HS and CS chains are 
created equally, with no preference for a specific HS/CS sequence of the saccharides or their 
modifications on specific syndecans [39]. More recently, some studies demonstrated that, for 
example, murine SDC-1 core protein contains five potential GAG attachment sites, three for HS 
and two for CS . Also several SDC-4 cDNAs have been characterized for rat, human and 
chicken and although rat SDC-4 possesses three functional GAG attachment sites capable of 
bearing either CS or HS chains, chicken SDC-4 core protein has three potential sites for GAG 
attachment, modified with HS side chains, and SDC-4 isolated from human tissues has only HS 
chains. Besides, it is not clear how much exact sequence of saccharides and their modifications 
play a role in the function of PGs [26]. 
 
In addition to the interactions mediated via their HS and CS chains, the extracellular domain of 
SDC-4 polypeptide core can be directly involved in protein–protein interactions, e.g. midkine and 
pleiotrophin bind not only to the GAG chains [40], but also to the core protein of SDC-4 [36], 
supporting the possibility of cooperation between core protein and GAG chains. Also, previous 
studies have demonstrated that the amino acid sequence diversity of syndecan extracellular 
domains results in distinct cellular functions [13, 24]. 
 
1.3.3.2 Transmembrane domain (TM) 
The syndecan transmembrane domain is composed of 25 hydrophobic amino acid residues and 
is responsible for dimerization/oligomerization of syndecan core proteins [41, 42]. These 
interactions are probably mediated through a strictly conserved GxxxG motif, which directly 
regulates homodimer formation of syndecans even in the presence of the strong anionic 
detergent sodium dodecyl sulfate (SDS), a property known as SDS-resistant dimerization [43]. 
The high concentration of this molecule in focal adhesions also favours this phenomenon [44]. 
Like other cell surface receptors, transmembrane domain-mediated non-covalent 
oligomerization appears to be crucial for the ability of syndecans to transduce signals from the 
ECM to the cytosol [41]. Multimerisation of SDC-4 has been detected using biochemical 
methods [45]. The function of such association is not clear but, for example in case of SDC-4, it 
has been shown to be required for activation of protein kinase C-α (PKCα) [45]. 
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1.3.3.3 Cytoplasmic domain 
The cytoplasmic domains of syndecans are relatively short, but contain three important regions: 
conserved regions 1 and 2 (C1 and C2) and a variable (V) region. The C1 domain, which is 
immediately adjacent to the inner leaflet of the cellular plasma membrane, is identical in all four 
mammalian syndecans (Figure 1.4) [26, 31]. 
 
 
Figure 1.4. The scheme and sequences of cytoplasmic domains of syndecans. The organisation of 
conserved (C1/C2) and variable (V) regions is shown with a summary of known interactions for each 
region. 
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The cytoplasmic domain is thought to be involved in 
syndecan dimerisation [46] and in binding of several 
intracellular proteins, including ezrin, Src kinase, and 
cortactin [47-49]. The C-terminal conserved C2 domain 
contains a PDZ-binding motif and one tyrosine residue. 
Four PDZ domain–containing proteins have been 
identified to interact with syndecans: syntenin [50], 
synectin, synbindin and calcium/calmodulin-dependent 
serine protein kinase [51-55]. The V domain is highly 
heterogeneous among the four mammalian SDCs. This 
region has been studied most extensively for  
SDC-4 because of its unique features, which are 
described in the following chapter. 
 
The interactions of cytoplasmic domains of 
transmembrane PGs, and SDCs in particular, with 
cytoskeleton are well established. However, the way how ligand interactions with HS chains 
transmit the appropriate signals through the core proteins is not yet clear. Similar to other 
receptors, SDCs can probably cluster in response to a ligand [45], although again, the molecular 
basis is unclear. Additionally, more recent developments show the importance of the 
ectodomain of the core protein in signal transduction [32]. There is growing evidence that the 
ectodomains may influence integrins, directly or indirectly, with further possibilities for affecting 
the ECM assembly or turnover [37]. As mentioned previously, all SDCs, apart from SDC-3, 
interact with ECM. 
 
In summary, SDCs hold a distinct position within the group of PGs, as these molecules are 
placed at the centre of signal integration in the cell and have been named "tuners of 
transmembrane signalling" [24]. They are called like that because they possess the unique 
function to integrate signalling from solute ligands (e.g. growth factors) and ECM proteins with 
other cellular receptor systems such as integrins. Moreover, their intracellular domains and 
interacting proteins can regulate a number of signalling pathways. 
PDZ domain 
The PDZ domain is a common 
structural domain of 80-90 
amino-acids found in the 
signalling proteins of bacteria, 
yeast, plants, viruses
 
and 
animals.
 
PDZ name comes from 
combining the first letters of 
three proteins — post-synaptic 
density protein 95 (PSD95), 
Drosophila disc large tumour 
suppressor (DlgA), and zonula 
occludens-1 protein (ZO-1) — 
which were first discovered to 
share the domain. PDZ domains 
often associate with other 
proteins, e.g. with syndecans,. 
and these combinations allow 
them to carry out their specific 
functions. 
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1.3.4 Syndecan-4 (SDC-4) 
As mentioned previously, it has been recognised that FA formation during cell spreading on 
fibronectin depends on the engagement of an integrin and a cell-surface proteoglycan, SDC-4 
(Figure 1.5) [4]. The unique feature of SDC-4 here is that it can become incorporated into FAs 
together with integrins [18, 56]. So far, no other syndecan and proteoglycan has been proven to 
play a role in FA assembly. Studies from several groups have confirmed that SDC-4 enhances 
FA assembly, although the essential role of integrins is also well-established [44, 57, 58]. The 
interactions of fibronectin, SDC-4 and integrins involve a series of downstream signalling 
events, including activation of tyrosine kinases by the integrins . At the same time, SDC-4 
cytoplasmic domain binds to membrane phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), 
which initiates an intermolecular conformational change that provides a binding platform for 
PKCα [17, 59-61]. 
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Figure 1.5. Fibroblast cells plated on fibronectin (a) with well distinguishable FAs (arrowheads). 
Cells grown on the isolated integrin-only ligand (b) spread but fail to form FAs unless stimulated 
with an antibody against SDC-4 (c) or a syndecan-binding fragment of the fibronectin (d). 
Formation of FAs upon adhesion to a SDC-4 ligand can be blocked by disrupting the expression 
of SDC-4 (e) or protein kinase Cα (f). This highlights the specific role of SDC-4 in adhesion-
contact formation and its immediate relationship with adhesion-driven signalling pathways. 
Images show fixed fibroblasts that have been immunofluorescently stained for the adhesion 
marker vinculin (green) and actin (red); scale bars represent 10 µm. Adopted from Morgan et al. 
Nat Rev Mol Cell Biol 2007 [4]. 
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SDC-4 certainly influences the cytoskeleton, since α-
actinin can directly bind its cytoplasmic domain [62] 
and SDC-4 ―knock-out‖ fibroblasts have been shown 
to display reduced organisation of actin with fewer 
microfilament bundles, perhaps indicative of a 
decreased tension exerted by the binding to the ECM 
[6, 19]. Such experiments support the function of the 
SDC-4 extracellular domain and its large GAG chains 
in cellular adhesion but the mechanisms involved are 
not yet fully understood [63]. 
On the other hand, there is an accumulating knowledge about the signalling events downstream 
of SDC-4 cytoplasmic tail, owing to the presence of well characterized PI(4,5)P2   [64], PKCα 
and PDZ binding sites in the cytoplasmic domain of SDC-4 (see Figure 1.3). It suggests that 
interactions might vary according to the circumstances, allowing syndecans to act as 
environmental sensors [14, 65]. 
  
A gene knockout 
“knock out” 
 
A gene knockout is a genetic 
technique in which one (or more) 
of the organisms genes is made 
dysfunctional ("knocked out" of 
the organism). It is used in 
learning about a gene that has 
been sequenced, but which has 
an unknown or incompletely 
known function. 
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1.4 B and T lymphocytes 
Human immunity consists of innate and adaptive systems. The innate immune system is 
capable of sensing viruses, bacteria, parasites and fungi through the expression of so-called 
pattern recognition receptors, which are expressed on the surface of macrophages, dendritic 
cells (DCs) and some other cells of the innate immune system [66, 67]. Adaptive immunity [68] 
is triggered when a pathogen breaks through the innate immune system and its sustained 
presence enables recognition of threshold levels of antigen. The cells of the adaptive immune 
system are special types of leukocytes called B and T lymphocytes, also called B and T cells . B 
and T cells are derived from pluripotent hematopoietic stem cells in the bone marrow [69] 
(Figure 1.6). 
 
 
Figure 1.6. All lymphocytes originate in the bone marrow. T cells, in contrast to B cells, then mature in 
thymus. Cytotoxic T cells directly attack foreign cells. Helper T cells stimulate B cells by cytokines and 
other co-stimulatory signals (e.g. CD40-CD40L interaction). Plasma cells which release antibodies into 
the bloodstream are produced at the late stage of B cell development. Antibodies are soluble 
immunoglobulin receptors binding pathogens present in the blood. Some B cells differentiate into memory 
cells with the capacity to rapidly respond to invasions of pathogens in the future (figure adapted from 
www.medspace.com [70]) 
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B cells are involved in the humoral immune response 
of higher organisms , whereas T cells are involved in 
cell-mediated immune response. Both B cells and T 
cells carry surface receptor molecules [67, 71] that 
specifically recognize ―non-self‖ molecules called 
antigens (e.g. peptides, glycostructures, etc). T cells 
recognize exclusively peptide antigens (small 
fragments of proteins from the pathogen) which have 
been processed and presented in the combination 
with a ―self‖ receptor called major histocompatibility 
complex (MHC) [72, 73]. This rather complicated 
process takes place in cells called antigen presenting 
cells (APCs). Nevertheless, MHC class I and II on the 
surface of APCs also present ―self-antigens‖ which are 
peptides derived from the organism‘s own proteins. 
Organisms have evolved mechanisms which ensure 
that self-peptides do not stimulate T cells [72, 74]. 
Unfortunately, there are situations when control 
systems do not function properly causing 
inappropriate immune responses. This may cause 
autoimmunity diseases or allergy [75].  
Each individual T cell (and B cell) possesses T cell receptors (TCRs; BCRs for B cells) with 
specificity for the single antigen [72, 76, 77]. This means, for example, that a T cell can be 
activated only when its receptor binds to this antigen in a complex with the MHC class I or II of 
the other cell. TCRs, as well as BCRs, are polyclonal which means that each T cell (and B cell) 
has different specificity defined by their specific receptor [78]. Recognition of MHC:antigen 
complex is aided by co-receptors expressed on the surface of T cells: CD4 on helper and CD8 
on cytotoxic T cells [79-81]. 
Antibodies (Abs) 
Antibodies, also known as 
immunoglobulins, are globular 
proteins that are found in blood 
or other body fluids of 
vertebrates, and are used by the 
immune system to identify and 
neutralize foreign objects, such 
as bacteria and viruses. They are 
typically made of basic structural 
units—each with two large heavy 
chains and two smaller light 
chains. General structure of all 
antibodies is very similar, but a 
small region at the tip of the 
protein, known as antigen 
binding site, is a highly variable 
structure, allowing millions of 
antibodies binding to different 
and specific targets, known as 
antigens. This large diversity of 
antibodies allows the immune 
system to recognize an equally 
wide variety of antigens. 
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1.4.1 Types of T cells 
1.4.1.1 Cytotoxic T cells 
Cytotoxic T cells (CD8-positive; CD8+) are a sub-group of T cells that directly kill cells infected 
with viruses (or other pathogens), or are otherwise damaged or dysfunctional (e.g. tumour 
transformed) [82]. In general, they attack other cells carrying foreign or abnormal antigens on 
their surfaces. Their TCRs recognise MHC class I antigen complex. Cytotoxic T cell activation is 
tightly controlled and generally requires a very strong MHC/antigen activation signal, or 
additional activation signals provided by "helper" T cells (see below) [83]. 
After activation [84], cytotoxic T cells release cytotoxins, such as perforin, which form pores in 
the target cell's plasma membrane. Once the membrane of the attacked cell is perforated, 
osmosis drives extracellular ions and water to enter the target cell until it bursts causing its 
death. The other way of cytotoxic T cells to kill infected or aberrant cells employs the possibility 
to activate a suicide mechanism – called apoptosis – in the target cell. Killing of host cells by 
cytotoxic T cells is particularly important in the prevention of virus replication [85, 86]. 
1.4.1.2 Helper T cells 
Helper T cells (CD4-positive; CD4+) have the capacity to regulate both innate and adaptive 
immune responses and help to determine which type(s) of immune response the body will 
generate for the eradication of particular pathogen(s) [87, 88]. These cells have no cytotoxic 
activity and do not kill infected cells or clear pathogens directly. Instead, helper T cells control 
the immune response by instructing the other cells, e.g. macrophages, to perform such tasks . 
TCRs of helper T cells recognize peptide antigen (derived from pathogens) bound to class II 
MHC molecules [77]. The MHC:antigen complex is also recognized by the helper cell's CD4 co-
receptor with the associated intracellular Lck effector kinase which mediates efficient T cell 
activation [76]. The activation of naive helper T cells requires longer duration of the engagement 
with APC [85, 89]. The activation of a helper T cell causes the release of specific cytokines that 
influence the activity of many other cell types [90]. For example, cytokine signals produced by 
helper T cells enhance the microbicidal function of macrophages or the activity of cytotoxic T 
cells [89]. 
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1.4.2 T cell receptor (TCR) 
The T cell receptor or TCR is a molecule found exclusively in T lymphocytes [91]. The TCR is 
composed of two different polypeptide chains (subunits). In 95% of T cells, these are alpha (α) 
and beta (β) chains (Figure 1.7). The remaining 5% express gamma (γ) and delta (δ) chains. 
The TCR, which is a type I transmembrane glycoprotein, consists of two subunits which form a 
dimer. For the α chain, the variable region is called Vα and the constant region is called Cα; for 
the β chain these are called Vβ and Cβ, respectively [92]. 
 
 
Figure 1.7. Domain organisation of TCR chains. In colours are shown the variable regions Vα, Vβ (dark 
and light blue) and the constant regions Cα and Cβ (white and black)  
 
The CD3 complex, which possesses four distinct chains (γ, δ and two ε) and a δ2 complex (also 
called CD247 in mammals), is assembled together with the TCR heterodimer . Subunits of the 
CD3 complex contain characteristic sequence motifs for tyrosine phosphorylation in their 
intracellular tails, known as ITAMs (Immunoreceptor Tyrosine-based Activation Motifs) [93]. The 
TCR polypeptides themselves have very short cytoplasmic tails, and all intracellular signalling 
events are probably mediated exclusively through the CD3 subunits. The CD3 and δ-chains, 
together with the TCR, form what is known as the TCR/CD3 complex (Figure 1.8) [93, 94]. 
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Figure 1.8. TCR/CD3 complex. Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) are shown in 
black. In light blue and white, dark blue and black - T cell receptor αβ chains, respectively; light grey - δ 
chain; dark greγ – γ chain; pale grey - ε chains; light/dark blue lines - δ homodimer. 
 
The essential function of the TCR complex is to recognize specific peptide antigen on MHC 
present on APC and elicit a distinct immune response [66]. Such recognition is enhanced by a 
tight contact formed between T cell and APC containing the unique antigen capable to cause T 
cell activation (details of the process in vivo described in following section). A large number of 
molecules are involved in the complex biochemical processes by which this activation occurs 
[92, 95-97] and of which only the main early and well documented events will be described in 
the following section. 
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1.4.3 T cell – APC interaction  
An individual T cell–APC interaction consists of three phases: initiation of the contact by T cell 
(also known as ‗contact acquisition‘); formation of an interaction plane (also called the 
immunological synapse (IS); see below); and, final phase, detachment of T cell which frequently 
continues to migrate (Figure 1.9) [77]. In vivo, the intercellular contacts are initiated by migrating 
T cells by their leading edge (showing similarities with the lamellipodium of motile fibroblasts) 
[98, 99] and are terminated by the re-initiation of the migration by the detachment from the APC 
[82, 100, 101].  
 
 
 
Figure 1.9. Phases of the interaction between T cell and APC. Figure taken from Fiedl et al. 
Nat. Rev. Immunol. 2005  [102]. 
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Three different physical states of the contact between T cells and APCs have been described 
(Figure 1.9) , all of which have an impact on the contact duration, receptor engagement and 
downstream signalling. 
First, well polarized, stable state results from the adhesion of T cell to APC after the recognition 
of cognate antigen [93, 98, 103]. Here, T cell rounds up and loses its migratory morphology, 
most notably, the posterior uropod is no longer detectable [104, 105]. Consequently, the lateral 
mobility of the cell is less than 1μm per minute, allowing receptor redistribution towards the cell–
cell junction (Figure 1.9) [106]. 
Second, the slowly mobile state is prevalently observed in cell–cell clusters between T cells and 
APCs in three-dimensional tissue environments, such as lymph nodes [102]. To achieve this 
state, a T cell ceases migration and polarizes towards an APC, but ongoing cytoskeletal 
dynamics at the contact zone of both cells generate slow, non-directional lateral mobility of  
1–2μm per minute. Therefore, with time, each cell changes position relative to the other, 
perhaps facilitating the receptor contact with the IS [71, 107]. 
Third, the migratory, or dynamic, junction results from the maintenance or re-initiation of the T-
cell migration on the surface of APC [73]. Such migratory state is characterised by partial 
polarisation, but with a dynamic leading edge that generates up front in the direction of the 
movement, a roundish cell body and a uropod that is 'dragged' behind [73, 82]. Migratory 
contacts have velocities of 1–10μm per minute, which leads to a rapid position change of the T 
cell on the surface of APC, and consequently, these interactions are associated with a rapid 
detachment. 
Although under numerous experimental conditions, one of these three states is usually 
dominant, the abovementioned status of the cell–cell interaction can convert during a single 
contact [73, 108]. Therefore, individual interactions can show sequential phases of the 
adhesion, slow lateral movement and dynamic crawling [109]. The type of interaction that 
occurs is determined by the initial maturation state of the T cell, the type of APC, the amount of 
antigen being presented by the APC and the location where the interaction takes place. The 
most important step is the contact time between the two cells when the IS is formed and the 
transmission of intracellular signals occurs [66].  
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1.4.4 The immunological synapse 
Early studies of both helper and cytotoxic T lymphocytes interacting with APCs presenting 
antigens demonstrated that the microtubule organizing centre (MTOC) and the cytoskeleton of T 
cells are orientated towards the APCs [103, 110]. These cytoskeletal changes, resulting in 
changes in T cell morphology and flattening of T cell on the surface of the APC, occur 
immediately after the initial antigen recognition [72, 111]. Work from the Kupfer and Dustin 
laboratories further demonstrated that, in addition to the morphological changes, receptor–
ligand complexes and signalling molecules involved in the adhesion and antigen recognition are 
organised into distinct domains or supramolecular clusters (see below) at the T cell–APC 
interface [104, 112]. This organisation is thought to help direct communication between two cells 
and has therefore been termed the ‗immunological synapse‘ (IS), due to its functional and 
morphological similarities to the well-known synapse formed between connecting neurons [90, 
106, 113, 114]. 
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1.4.4.1 Stable IS 
The stable IS (also known as the monocentric IS results from a polarised interaction between T 
cell and APC in the presence of cognate antigen [91]. In vitro, it frequently lasts 30 minutes or 
longer. It is defined by the recruitment and segregation of cell-surface receptors and adaptor 
proteins at the cell–cell junction, and was reported to be responsible for sustained transmission 
of the intracellular signals. The development of the IS comprises five phases [106, 115]:  
1. cellular scanning, contact acquisition and adhesive arrest;  
2. early IS assembly and signalling;  
3. maturation and receptor segregation;  
4. TCR internalisation; 
5. IS dissolution.  
 
Progression through all of these phases requires continuous pMHC–TCR interaction, sustained 
membrane-proximal signalling and an intact T-cell cytoskeleton [93, 99]. Although the processes 
that regulate the first four phases have been studied in detail, the processes that control the IS 
resolution and T-cell detachment are less well described [70]. 
 
1.4.4.1.1 Cellular scanning, contact acquisition and adhesive arrest  
The first phase of the IS formation occurs when moving T cells recognise the immunogenic 
peptide–MHC complexes which activates lymphocytes function activation integrin – 1 (LFA-1) 
high affinity form for binding of intercellular adhesion molecule 1 (ICAM1), leading to a 
temporary arrest in migration, known as a ‗stop signal‘ [77].  
1.4.4.1.2 The IS assembly and signalling  
The second phase in the 'life' of the IS is the essential phase for the optimal signalling and is 
therefore crucial for determining the outcome of the T-cell–APC interaction. Within first few 
seconds of contact, calcium signalling [66, 116] — followed by the recruitment of signalling 
molecules such as CD3δ, Lck, ZAP70 and their phosphorylation — is observed [91]. In next step 
ZAP70 targets the membrane-anchored adaptor molecule LAT (linker for activation of T cells), 
which contains many ITAMs to which downstream effector molecules can bind [95].  
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A mature immunological synapse is formed at the cell–cell junction within 5–30 minutes of 
continuous T-cell–APC interaction [91, 106]. Maturation was defined by molecular segregation, 
which leads to a central zone containing subunits of the TCR/ CD3 complex, as well as 
associated PKCθ. This zone was named the central supramolecular activation cluster (cSMAC). 
It is surrounded by a ring-like zone with accumulated LFA1 and talin, which is known as the 
peripheral SMAC (pSMAC) and also as adhesive ring without which the IS formation is 
impossible [117] and a more distal zone rich in CD45, which is known as the distal SMAC 
(dSMAC) [104].  
Although the organisation of ‗classical‘ ISs has been the subject of intense study, non-classical 
ISs have been also observed under various conditions (Figure 1.10) [73, 114]. Mature IS has 
been mainly studied in T and B cells and T cells and planar bilyer interactions. It is less evident 
in T cells with DC interactions and in vivo , raising questions about its physiological significance. 
Also, experiments with conjugates fixed at various time-points and studies utilising time-lapse 
microscopy demonstrated that the IS formation is a dynamic process involving a variety number 
of intermediate profiles [112].  
Imaging of the formation of the immunological synapse showed that the accumulation of antigen 
receptors in the centre of the synapse is preceded by microclustering of the antigen receptors in 
the periphery [118, 119].  Once formed, the microclusters are transported to the centre of the 
synapse by an actin-dependent process [118]. The synaptic microclusters appear to be the 
platforms for receptor activation and signal propagation. For example, microclusters recruit 
signalling molecules such as Src kinases and ZAP-70 [120]. They also exclude inhibitory 
phosphatases such as CD45 [94, 118]. However, many of the molecular mechanisms of antigen 
receptor activation inside these structures remain beyond the resolution of optical microscopy 
and could not be directly addressed by conventional imaging. Nevertheless, the results of the 
high-speed PALM imaging showed that TCRs on resting T cells were pre-clustered in small 
areas of about 70–140 nm in diameter called as ‗protein islands‘ [96]. The islands were enriched 
in cholesterol and anchored by actin filaments. Antigen stimulation led to a more pronounced 
clustering of the TCR, with more TCRs present in the islands and multiple islands aggregating 
together. Taking into account the rapid movement of receptors seen in the single molecule 
studies, these results indicate that there is a dynamic partitioning of receptors into the islands in 
resting lymphocytes and that antigen-induced stability of the islands mediates immobilization of 
receptors and signalling molecules after activation [96, 121]. 
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Specialized effector and downregulatory functions of the cSMAC are also suggested by its 
absence or modification according to cell-type. Prototypical cSMAC/pSMAC patterning, as 
originally described in T–B cell interfaces, is not commonly observed in T-cell interfaces with 
dendritic cells [122], and are absent from thymocyte interfaces [79]. Cytotoxic T cells appear to 
form a modified IS, in which the central region is divided between a TCR-rich cSMAC and a 
secretory domain for delivery of lytic granule [90]. 
TCR proximal signalling is thought to occur in TCR-rich submicrometer-scale plasma membrane 
domains which form almost instantaneously upon T cell contact with antigen-bearing surfaces in 
all T cell subtypes studied. These TCR microclusters form throughout the contact interface 
following TCR ligation [118], and after a brief stationary phase, translocate centripetally to 
assemble into the cSMAC. Signalling microdomains have recently emerged as a general 
organizing principle of spatially regulated signalling in lymphocytes and other cells [123, 124], 
leading to the suggestion that ligand-induced microclusters may constitute the basic signalling 
unit that initiates and organizes immune cell signalling [118, 120, 125]. 
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Figure 1.10. The immunological synapse organisation. Examples of classical (a) and multifocal 
(b) immunological synapses (ISs) are presented. The fluorescence images are from 
experiments where CD4+ T cells were activated on supported planar bilayers containing 
fluorescently labelled pMHC and ICAM-1. TCR–pMHC and LFA-1–ICAM-1 interactions are 
green and red, respectively, in both representative diagrams and fluorescence images. 
Differential interference contrast (DIC) images are shown on the right to illustrate the shape of 
the cells. The scale bars represent 5 μm (modified from [114]). cSMAC (central supramolecular 
activation cluster) and pSMAC (peripheral supramolecular activation cluster) represent the 
classification of areas of the IS according to Kupfer and colleagues. Figure adopted from 
Thauland et al Immunology 2009.  [114]. 
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1.4.4.1.3 TCR internalisation 
In the later stage, during sustained signalling, the TCR is internalised to cytoplasmic vesicles in 
the cSMAC, thereby limiting its availability at the interaction plane [105]. This downregulation of 
the TCR is certainly important for the function, because it is predicted to contribute to the 
diminishment of the signalling [105], and, ultimately, to the last phase of the IS — contact 
resolution [95]. 
 
1.4.4.1.4 The IS resolution 
The IS resolution occurs when the T cell and APC detach. In the most cases, the interactions 
are resolved by the re-onset of the migration of either cell. During detachment, portions of T-cell 
membrane (including the receptors they contain) can remain attached to (or fuse with) the APC 
(and vice versa), potentially causing focal zones of continued signalling [86]. It is unclear, 
however, whether the IS resolution is a prerequisite or a consequence of cell detachment [108]. 
At present, the mechanisms that have been proposed to elicit termination of the IS signalling 
and resolution of contact are based mainly on circumstantial evidence, and how these 
mechanisms would support the termination of the contact as a morphological process remains 
unclear.  
It is important to note that the molecular events underlying the phases of stable IS formation and 
resolution also occur during the formation of other synaptic structures  (Figure 1.10b), although 
the extent of TCR clustering and the identity of the recruited receptors can vary [76, 108, 119]. 
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1.4.5 T cell activation 
T cell activation results from signals delivered after the binding of ligands present on the surface 
of APCs to the TCR and co-stimulatory receptors on T cells [112, 126]. Moreover, the 
recognition of peptide antigens and the subsequent activation requires the physical interaction 
of T cells with APCs (e.g. LFA-1/ICAM-1 interactions). The migration and morphological 
reorganisation of T cell are essential for its activation [103]. The number of molecules (e.g. LFA-
1, CD28, CD86) are responsible for the regulation of the cell‘s contact [67, 119]. Adhesion of the 
T cell to the APC is crucial for the prolonged contact required for proper activation. 
In addition to peptide antigens presented by MHC molecules, T cells can be activated with 
superantigens (SAgs) [127-129], a system used in our project. SAgs are disease-causing 
bacterial toxins [130] that are capable of interfering with the human immune system by 
crosslinking the TCR and MHC class II through the variable Vβ-domain of TCR (Figure 1.11) 
[92, 131, 132]. SAgs induce a massive release of cytokines and hence elicit a very strong 
immune response [131]. 
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Figure 1.11. Differences in TCR-pMHC crosslinking of the peptide-antigen and a superantigen 
driven event. 
 
It has long been known that one reason for SAg potency is that the fraction of T cells that 
recognize and respond to particular SAgs (up to 20% of all T cells) is much larger than that 
which recognizes and responds to conventional antigens (about 0.001% of all T cells)[92]. In 
part, this is because, unlike peptide antigens, individual SAgs can bind either MHC II α or β 
chains [131, 133], or, in some instances, both. In addition, T cell recognition of SAg is linked to 
the expression of TCR β chain of a particular Vβ family [92, 132] and not to specific αβTCR 
clonotypes . Therefore, the number of potentially responsive T cells is much higher for given 
SAg than for an individual protein antigen. 
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More recently, crystallographic analysis has shown that SAgs do not interact with either the 
MHC or the TCR in the same way as conventional antigens [134]. Peptide antigens are folded 
into the antigen-binding cleft of MHC molecules, which are recognized in a head-to-head 
orientation by the TCR, which allows the co-receptors, CD4 or CD8, to bind to the membrane-
proximal domain of the MHC molecule simultaneously [131]. In contrast, SAgs bind MHC II 
molecules outside of the peptide-binding groove and bridge the TCR to the MHC through an 
interaction with the external face of the TCR Vβ chain. Moreover, the co-receptor CD4 is not 
required for the recognition of SAgs, and in consequence, SAgs can stimulate both CD4+ and 
CD8+ T cells [92]. 
Despite the differences in the way peptides and SAgs drive MHC–TCR interaction, it has been 
widely assumed that stimulation of T cells by SAg mimics stimulation by antigen. SAgs have 
affinities for TCRs similar to those for pMHC, and their dissociation rates from TCRs are 
comparable to those measured for TCR-pMHC interaction [133]. Therefore, the stimulation of T 
cells with SAgs was assumed to resemble antigen stimulation of the TCR more closely than 
stimulation by means of cross-linking with antibodies directed against the subunits TCR/CD3 
complex (usually strengthened by secondary antibody or immobilisation), as the latter have 
much higher affinity for TCR and slower dissociation rates. The most common mix of antibodies 
used for T cell activation are anti-CD3 and anti-CD28 antibodies against the ε subunit of the 
TCR complex and a co-receptor CD28 [135]. 
1.4.6 Adhesion in T cell activation 
In the absence of antigen, T cells move rapidly within the lymph nodes (LNs), forming transient 
contacts with APCs that allow T cells to ―scan‖ APCs for the presence of the cognate antigen 
[82]. Chemokine gradients present in the LN microenvironment may promote T cell scanning of 
APCs by activating LFA-1. Chemokine-stimulated increases in LFA-1 affinity are both extremely 
rapid and transient, characteristics that would support T cell scanning of APCs, but retain the 
specificity of the process . The scanning process by itself may promote integrin activation and 
facilitate more prolonged interactions between T cells and APCs [136]. The encounter of naïve 
CD4+ T cells with class II MHC-presenting self-peptide in the periphery promotes polarization of 
the TCR and signalling molecules, such as ZAP70, to the sites of T cell–APC contact [91]. 
Although LFA-1 distribution was not assessed in these studies, this tonic level of activation may 
polarise LFA-1 or shift the conformational equilibrium toward the higher affinity LFA-1 that 
facilitates T cell scanning [136, 137]. 
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An external ring of LFA-1 surrounding a central TCR-rich region is a structural hallmark of a 
mature IS, which forms during the antigen-dependent T cell interactions with APCs [104, 112, 
126] (as mentioned in section 2.3). Furthermore, studies using planar lipid bilayers have 
established that the IS can form when a T cell interacts with only pMHC complexes and ICAM-1 
[112]. During the initial stages of T cell activation, LFA-1 is localized in the centre of the T cell–
APC contact site while the TCR localizes primarily to the periphery [94, 112, 126]. Rapid 
clustering of LFA-1 coupled with its central localisation within the contact site suggests that LFA-
1-mediated adhesion is needed to stabilize T cell–APC contact, resulting in a larger number of 
engaged TCRs and activation of signalling cascades required for T cell activation. This is 
supported by colocalisation of the TCR and activated tyrosine kinases, Lck and ZAP70, in the 
periphery of the IS [94, 126], which suggests that signalling cascades necessary for T cell 
activation are already initiated while LFA-1 and ICAM-1 are still clustered in the centre of the T 
cell–APC contact site.  
T cell commitment to proliferation and effector function requires sustained T cell–APC 
interaction [84, 91, 138]. In the mature IS, the TCR moves to the centre of the T cell–APC 
contact site while LFA-1 translocates to more peripheral parts of the IS [91, 94, 139]. The 
kinetics of LFA-1 localisation to the IS correlate with the minimum amount of conjugation time 
necessary for T cell proliferation to occur [91, 139], suggesting that prolonged localisation of 
LFA-1 may facilitate molecular engagements at the T cell–APC contact site that result in 
signalling events necessary for complete T cell activation. 
It is also important to note that factors such as the differentiation state of the T cell, the type of 
APC and the microenvironment where the T cell interacts with the APC may affect the initiation, 
maintenance, and functional consequences of IS formation. Memory T cells generally express 
higher levels of LFA-1 and other integrins than naïve T cells do, and thus memory T cells have 
enhanced basal and TCR-dependent integrin function [140]. These differences in integrin 
functions between naïve and memory T cells likely affect both the T cell scanning process and 
IS formation. Furthermore, effector T cells have elevated integrin activity when compared to 
resting memory T cells, and they likely interact with collagen and other ECM proteins in 
peripheral tissues.  
Therefore, if integrins are involved in the process of IS formation and stabilisation, there is the 
possibility that proteoglycans may also be. Studies showing the expression profile of SDC-4 in T 
cells raised the idea to study the involvement of SDC-4 in T cell activation. 
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1.4.7 SDC-4 expression in lymphocytes and other cells of the immune 
system 
SDC-4 has been a molecule of interest for a long time and much is known about it (section 1.4). 
On the other hand, its function and influence on cells of the immune system have got attention 
only recently and from very few groups. 
All published data confirm ubiquitous and, at the same time, tightly regulated expression of 
SDC-4 in all cells, including T cells. Ariizumi and co-workers demonstrated increased 
expression of SDC-4 in activated mouse [141, 142] and human T cells [143] in comparison to 
their resting (naïve) counterparts. On the other hand, SDC-4 is constitutively expressed at high 
levels in B cells and monocytes [144]. An increase in SDC-4 expression has been reported after 
lipopolysaccharide (LPS) stimulation of macrophages and DCs [145, 146]. 
 
1.4.7.1 Inhibitory effect 
T lymphocyte activation is regulated by stimulatory, co-stimulatory and inhibitory signals 
transduced together with those induced by the binding of TCRs to their corresponding ligands 
on APCs [80]. Stimulatory receptors tend to be present constitutively even on resting T cells, 
whereas inhibitory receptors require primary activation for their expression [147]. Akiyoshi and 
co-workers characterised a novel inhibitory pathway in T cells, which is transduced by the 
interaction of the highly glycosylated APC surface molecule dendritic cell-associated heparan 
sulphate proteoglycan-dependent integrin ligand (DC-HIL) and SDC-4 as its exclusive receptor 
[141, 143, 148, 149]. DC-HIL specifically recognizes a particular structure of heparan sulphate 
specific for SDC-4 [141, 150]. This binding strongly attenuates the response to anti-CD3 
antibodies, which can activate murine T cells. In T cells, it also causes a block in the production 
of proinflammatory cytokines and in their proliferation. These data suggest that DC-HIL/SDC-4 
interaction can inhibit the T cell activation process in vivo [141]. 
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The inhibitory role of SDC-4 in T cells was also studied 
by Espel‘s group [142]. They examined whether anti-
SDC-4 antibodies could hinder in vitro T cell 
alloreactivity requiring cell-cell interactions. They looked 
at the stimulatory response of cells in a mixed 
lymphocyte reaction (MLR). The cells were incubated in 
the presence of an anti-SDC-4 Abs which partially 
inhibited proliferation; control cells proliferated normally. 
The combination of anti-SDC-2 and anti-SDC-4 Abs did 
not inhibit proliferation further. These findings support 
the evidence that SDC-4 may have an inhibitory 
function during the activation of primary T lymphocytes 
(human as well as murine).  
The abovementioned MLR stimulation in presence of anti-SDC-4 Abs suggested that SDC-4 
plays an important role during T cell stimulation. Further studies showed that the inhibition of T 
cell proliferation by cross-linkage of SDC-4 was independent of the accessory cells [142]. The 
same effect of proliferation inhibition was observed when purified T cells (from unseparated 
peripheral blood mononuclear cells (PBMCs)) were cultured on anti-CD3 plus anti-SDC-4-
coated plates. This means that extensive cross-linking of SDC-4 on T cells leads to the 
inhibition of T cell proliferation stimulated with anti-CD3 antibodies. This suggests that cross-
linked SDC-4 Abs have higher inhibitory capacity on T cells than soluble Abs (MLR above). 
Moreover, cross-linking of SDC-4 also inhibited anti-CD3 Ab-induced TNFα production by CD4 
T cells in a dose-dependent manner. These results show that SDC-4 has an inhibitory function 
in human T cells, in agreement with what has been suggested for SDC-4 in mouse and human 
T cells by Ariizumi and colleagues [141, 143]. 
  
Mixed lymphocyte reaction 
(MLR) 
Peripheral blood lymphocytes 
from two individuals are mixed 
together in tissue culture for 
several days. Lymphocytes from 
incompatible individuals 
stimulate each other (alloreactive 
reaction) to proliferate 
significantly whereas those from 
MHC compatible individuals do 
not. 
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1.4.8 SDC-4 effect on maturation, motility and morphology 
Interesting studies emphasizing the function of SDC-
4 in cells of the immune system have been 
performed by the Buhlingen group. They 
demonstrated that SDC-4 is upregulated in human 
monocyte-derived dendritic cells (DCs) during their 
maturation. Increased presence of SDC-4 influenced 
the motility of DCs to lymphatic tissues [151]. 
Maturation and motility of DCs, following contact with an antigen, are crucial steps of the 
immune response [152], as well as of maintenance of tolerance. Both processes are important 
steps of the antigen-specific adaptive immune response during which mature DCs present the 
processed antigens to T cells in secondary lymphatic tissues. DCs stay in tissues from where 
they migrate into lymph nodes. There they contact number of T cells, what is regulated by actin 
driven processes.  
Averbeck and co-workers investigated the effects of lysophosphatidylcholine (LysoPC) on DC 
motility. In addition, they investigated the effect of LysoPC on the involvement of PKCδ 
phosphorylation-dependent regulation of DC motility by SDC-4 and PKCα [153]. LysoPC is 
generated during the apoptosis of cells and acts as a ―find-and-eat-me‖ signal thought to 
prevent autoimmunity [146]. This molecule also upregulates the surface expression of MHC and 
co-stimulatory molecules, e.g. CD86 in DCs, but has no effect on the expression of SDC-4. 
Furthermore, LysoPC-induced SDC-4 phosphorylation leads to a decrease in adhesion, 
podosomes formation and mobility of DCs.  
Buehligen and co-workers also showed that LysoPC inhibits the adhesion of DCs to fibronectin 
and their motility by decreasing podosomes formation. What seems to be important for my 
project is that DC podosomes formation and motility are both regulated by SDC-4. Moreover, 
both processes are controlled by PKCδ-dependent phosphorylation of SDC-4 and were inhibited 
in LysoPC-matured DCs. Thus, these DCs are defective in adhesion and migration that might 
delay migration of DCs to lymphoid organs and thus prevent autoimmunity. Buehligen and co-
workers found that LysoPC stimulation decreases motility and adhesion in immature and mature 
DCs, which suggests that the adhesive events are independent of maturation. They have also 
previously shown that a shift from intracellular to cell surface-associated SDC-4 occurs during 
the maturation of DC [146, 151]. 
Podosomes 
Podosomes are the first sites of 
integrin-stimulated actin 
polymerization in leukocytes. 
They are similar in composition 
and structure to the invadopodia 
found in fibroblasts. 
53 
Yamashita and co-workers demonstrated another effect of SDC-4 on the morphology of immune 
system cells. Activated murine B lymphocytes, when seeded on a SDC-4 antibody-coated 
surface, exhibited dramatic morphological changes such as the formation of well-distinguishable 
and large fillopodial extensions. In consequence, SDC-4 was proposed to increase the cell size 
[154]. 
In summary, SDC-4 regulatory effect on DC‘s adhesion and their motility, and B cells 
morphology, together with changes in SDC-4 expression in T cells, brought us to the idea that 
SDC-4 may influence the T cell activation process when recognising the antigen on the surface 
of APCs. 
The general recapitulation of the published knowledge on SDC-4 function and characteristics in 
mammalian cells is a s follows: 
 It is present in FAs and influences junction assembles between cells [114] 
 SDC-4 in coordination with fibronectin [20, 65, 155] and integrins [4, 5] is involved in a 
number of downstream regulation processes including activation of tyrosine kinases 
 SDC-4 highly affects cytoskeleton organisation [62, 156], and it may possible be its 
effect in IS as actin organisation is highly reorganised during IS formation 
 SDC-4 is a binding partner for many proteins, e.g. PDZ [52], but may influence indirectly 
other receptors e.g. TCRs [88,90] 
 The association of SDC-4‘s extracellular core protein domain and other cell surface 
molecules may mediate cell-cell adhesion or potentially function as a shed or matrix-
embedded adhesive ligand - adhesion is important for T cell activation. 
 
Recent publications of a few groups which already described expression changes in T cells 
made us more interested in the interaction or correlation between the molecule and these cells 
[142, 143, 148, 150]. 
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1.5 Agrin 
Interstingly, another heparan sulphate proteoglycan agrin has recently also been implicated to 
function as a co-stimulatory signal at the immunological synapse [157].  
Agrin is a heparan sulphate proteoglycan with a large core protein backbone that includes a 
number of distinct structural domains. There are extensive O- and N-linked glycosylations at the 
amino-terminal half of the protein with the addition of heparan sulphate GAG at the O-linked 
carbohydrate moieties [158]. The transcript of the Agrin gene can be differentially spliced to 
produce different isoforms of the protein, which determine its localization and function. 
Alternative splicing at the amino terminus produces either a type II transmembrane protein (TM-
Agrin) or a secreted protein (SS-Agrin) [159, 160].  
Expression of Agrin in T cells has been documented by Western blotting, and PCR. Initially, 
Khan and colleagues [157] reported its expression in murine thymocytes and splenocytes, and 
demonstrated that following T cell activation it is post-translationally modified. Co-stimulation 
with anti- CD3 and anti-Agrin antibodies augmented T cell proliferation, particularly when low 
concentrations of the anti-CD3 antibody were used. Furthermore, purified Agrin from activated, 
but not resting, T cells when added to the culture medium of non-activated T cells induced 
clustering of lipid rafts [161] and of the TCR [157] . Also, Agrin was localized at the IS during 
antigen presentation [157, 162]. It has been reported that agrin lowers the threshold for antigen-
induced lymphocyte proliferation  in vitro by recruiting lipid rafts that contain complexes of CD3 
and T-cell receptors, CD4 or CD8, and Lck [157]. It functions on lymphocytes at picomolar 
concentrations and within minutes.  As mention earlier, Agrin is present in resting, as well as 
activated, T cells, but interestingly only deglycosylated form isolated from activated T cells 
induces TCR aggregation and recruitment of lipid rafts [163] as observed at the immunological 
synapse [164]. Given that agrin's function in T cells is regulated by glycosylation and that agrin 
aggregates lipid rafts, its deglycosylation might induce cytoskeletal reorganization in T cells. So, 
on T-cell activation, the deglycosylation of agrin could eventually allow its dissociation from the 
CD44–agrin complex and the delivery of the accompanying lipid rafts to the immunological 
synapse [164]. Based on these results, it was proposed that T cell activation induces an as yet 
unknown modification of Agrin that endows it with higher aggregating activity, and furthermore 
redistributes the protein to the site of the IS where it may facilitate antigen presentation [164].  
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1.6 Hypothesis and Aims 
1.6.1 Hypothesis 
This project is aimed to add another perspective to the ongoing research studying factors 
influencing the formation and stability of the immunological synapse (IS) formed between T cells 
and APC. More specifically, the poorly understood involvement of proteoglycans in this process. 
I particularly studied one member of this protein superfamily, SDC-4 with its extensive 
glycosaminoglycan moieties exposed to the extracellular space surrounding the cells 
(glycocalyx). SDC-4 has been found previously to influence the contact with neighbouring cells. 
Specifically, I hypothesised that SDC-4 would play a role in T cell-APC interaction by affecting 
IS formation and/or stability, and designed experiments to test this.  
1.6.2 Aims 
My aims to test the hypothesis were: 
 To confirm the expression profile of SDC4 in naïve and activated human peripheral T 
cells as well as the Jurkat T cell line using available methods. SDC-4 is expressed in T 
cells at low level, but it is the only known syndecan which was reported to be up-
regulated by T cell activation [141-143] 
 To localise SDC4 in activated T cells and study its co-localisation with the T cell receptor 
and proximal signalling molecules using immunofluorescence. 
 To test the possibility of involvement of fibronectin, an extracellular ligand of SDC-4, in 
IS formation and stabilisation using immunofluorescence. 
 To quantitate the impact of SDC4 on conjugates formation using flow cytometry.  
 To study the dynamics of the IS in the presence or absence of increased level of SDC-4 
expression employing live cell imaging and quantitative image analysis. 
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2  Materials and methods 
2.1  Materials and suppliers/sources 
2.1.1 General reagents and chemicals 
Ampicillin          Stratagene 
Ammonium persulphate        Sigma  
Acetic acid          Merck  
Bis-Acrylamide         Biorad  
Bromophenol Blue         Sigma 
Bovine Serum Albumin (fraction V)       Sigma 
Coomassie Brilliant Blue G-250       Biorad 
Dithiothreitol (DTT)         Sigma 
dNTP set          Invitrogen 
Ethylenediaminetetraacetic acid (EDTA)       Merck 
Ethanol          Merck 
Ethidium bromide         Biorad 
Formaldehyde          Sigma 
Geneticin sulphate (G418)        Invitrogen 
Glycerol          Sigma 
Methanol          Merck 
Octylglucoside (OG)         Sigma 
Phosphate buffered saline         Invitrogen 
Potassium chloride         Sigma 
Propan-2-ol/isopropanol        Merck 
Sodium azide          Sigma 
Sodium dodecyl sulphate (SDS)        Merck 
Sodium hydroxide         Merck 
Sucrose          Sigma 
N,N,N',N'-Tetramethylethylenediamine (TEMED)     Biorad 
Triton X100          BDH 
Tris(hydroxymethyl)methylamine (Tris base)      Merck 
Trizol® Reagent         Invitrogen 
Tween-20          Sigma 
 
2.1.2 Molecular biology enzymes and reagents 
Agar           Invitrogen 
Bovine serum albumin (BSA)        Invitrogen 
Complete mini protease inhibitor cocktail      Roche 
1 kb DNA ladder         Invitrogen 
500bp DNA ladder         Invitrogen 
Lipofectamine 2000          Invitrogen 
Luria-Bertani (LB) broth        Sigma 
Needles           Kendall, UK 
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RNase A          Qiagen 
OligodT          Invitrogen 
Protein G beads         Amersham 
SDS-PAGE Protein all blue ladder       Biorad 
S.O.C. medium         Invitrogen 
Taq DNA polymerase         Qiagen 
 
2.1.3 Molecular biology kits 
Qiagen endofree plasmid maxi kit        Qiagen 
Taq PCR kit           Invitrogen 
Dynabeads® Untouched™Human CD4 T Cells separation kit   Invitrogen 
 
2.1.4 Tissue culture reagents and materials 
Coverslips          VWR, UK 
Cryotubes          Nunc 
BDCytopern/Cytofix™        BD 
Dimethyl sulphoxide (DMSO)         Sigma 
Dulbecco‘s Modified Eagle Medium (DMEM)     PAA 
Foetal Calf Serum (FCS)        PAA 
OptiMEM®          Invitrogen 
Penicillin          PAA 
Kanamycin          Sigma 
Phosphate Buffered Saline (PBS) (without calcium and magnesium)  PAA 
RPMI 1640 medium         PAA 
Sodium pyruvate         PAA 
General microscopy slides        VWR 
Tissue culture and microbiology plastic ware : NUNC, BD Biosciences, Falcon, FisherScientific 
Trypsin-EDTA          PAA 
WILCo-dishes          Intracel, UK 
 
2.1.5 Western blotting equipment and materials 
PROTRAN® Nitrocellulose transfer membrane  Whatman International Ltd, UK 
SDS-PAGE gel tanks         BioRad 
Western Semi-Dry Blotting Machine    Hoeffer, Germany 
3MM paper       Whatman International Ltd, UK  
Amersham™ ECL Western Blotting Detection System   GE Healthcare 
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2.1.6 Equipment 
Centrifuge tubes      Falcon ref.352052 BD Biosciences 
Eppendorf 5810 centrifuge       Eppendorf, Germany 
Eppendorf 5415R centrifuge       Eppendorf, Germany 
FACS Calibur         BD Biosciences, UK 
FACS BD LSR II        BD Biosciences, UK 
Ettan DIGE Imager         GE Healthcare, UK 
MWG, DNA thermal cycler       MWG, Germany 
Micro Centaur microcentrifuge       Scotlab, UK 
Sorvall RC-5B centrifuge        Sorvall, UK 
Sorvall RT-7          Sorvall 
Storm 820 gel drier         Pharmacia Biotech 
Tissue culture CO2 incubator        Nuaire 
2.1.7 Plasmids 
pEGFP-N1         gift from J.Couchman 
pHA-rSDC-4-IRES-EGFP       gift from J. Couchman 
pIRES2-EGFP        Clontech 
pMEX-hSDC4         gift from J. Couchman 
pHA-hSDC-4-IRES-EGFP     created in the group of A.I. Magee 
2.1.8 Bacterial strains 
XL10 Ultracompetant cells                       Tetr -hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F‘ proAB lacIq  (Tetr) Amy Camr]a  
         Stratagene 
DH5α subcloning efficient cells  
F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 
gyrA96 relA1 λ-         Invitrogen 
2.1.9 Mammalian cell lines 
Jurkat T cells        gift from J. Burkhardt lab 
HEK293A cells         ATCC 
MD-MBA-231 cells         ECACC 
MRC5 cells          ECACC 
Raji B cells        gift from J. Burkhardt lab 
OKT3 hybridoma         ATCC 
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2.1.10 Buffers  
Cell Lysis Buffer: 1% Octylglucoside (OG) in TNEPF + 1mM DTT, (150mM NaCl, 1.5mM 
MgCl2, 50mM NaF, 1mM Na3VO4)  
5X Electrophoresis Running Buffer: 0.6M Tris Base, 0.5M Glycine, 0.05% (w/v) SDS, distilled 
water to 1 litre and pH 8.3. 
DNA loading Buffer: 6mM EDTA, 300mM NaOH, 18% Ficoll (in water), 0.15% Bromocresol 
Green, 0.25% Xylene Cyanol  
Fixation Buffer: 4% paraformaldehyde + 2% sucrose in 25ml PBS, 400µl 1M NaOH, 200µl 1M 
HCl 
SDS-PAGE Sample Buffer (SB): 100 mM Tris, pH 6.8, 2% SDS, 5% ß-mercaptoethanol, 15% 
glycerol 
5X Transfer Buffer: 25mM Tris, 0.05% SDS, 20% (v/v) Methanol, made to 1000ml with distilled 
H2O. 
RIPA Buffer: 50mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 0.5% Triton X100, 0.5% Sodium 
deoxycholate (need to pH with NaOH), 0.1% (w/v) SDS (optional) plus mini complete/EDTA 
cocktail of inhibitors. 
PBS-T: 0.05% (v/v) Tween-20 in 1X PBS  
SDS-PAGE Gel Buffers stocks:  
Lower Tris Buffer pH 6.8: 1M Tris,  
Upper Tris Buffer pH 8.6: 1M Tris,  
WB Blocking Buffer: 5% (w/v) non-fat dried milk powder in PBS-T and filtered through 5MM 
blotting paper 
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2.1.11 Antibodies and immunofluorescence reagents 
Antibody 
Raised 
In 
Type 
Concentration 
Used 
Supplier 
Anti-HA tag (HA.11)    Mouse Mo IgG1 1:2000  Covance, USA 
Anti-CD25 APC Mouse Mo 1:200 BD Biosciences, USA 
Anti-CD4 FITC Mouse Mo 1:200  BD Biosciences, USA 
Anti-Lck Rabbit Po 2166 1:100 
Generated in our group 
(A.I. Magee) 
Anti-Lck, 3A5 Mouse Mo  1:100 
SantaCruz Biotech., 
USA 
Anti-Mouse 
IgG1conjugated to: 
Alexa Fluo®488 
Alexa Fluo®647 
Goat Po 1:200 Invitrogen, UK 
Anti-Mouse IgG2a 
conjugated to: 
Alexa Fluo®555 
Alexa Fluo®647   
Goat Po 1:200  Invitrogen, UK 
Anti-Mouse IgG2b 
conjugated to: 
Alexa Fluo®555 
Alexa Fluo®647  
Goat Po 1:200  Invitrogen, UK 
Anti-Rabbit Ig Goat Po 1:1000 Invitrogen, UK 
Anti-Phosphotyrosine, 
4G10 
Mouse 
Mo, 
IgG2b 
1:10000 Millipore 
Anti-rSDC-4, 5G9 Mouse Mo 1:50 (IF) 
SantaCruz Biotech., 
USA 
Anti-rSDC-4, 5G9- PE Mouse Mo 1:50 (IF) 
SantaCruz Biotech., 
USA 
Anti SDC-4, ab24511  Rabbit  Po 1:200 (IF) AbCam 
Anti TCR, OKT3 Mouse  Mo 2µg/ml Lab creation 
α-Tubulin, DM1A Mouse Mo 1:200 AbCam 
Phalloidin Alexa 568 D.A.  1:200 Invitrogen, UK 
Table 2.1. Antibodies used. WB = dilution for Western Blotting; IF = dilution used for 
Immunofluorescence; Mo and Po stand for Monoclonal and Polyclonal antibodies, 
respectively.D.A = does not apply. 
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2.2 Methods 
2.2.1 Antibody Production using BD CellTM MAb Medium in a 
CELLineTM Device 
The CELLineTM is a novel cell culture system based on nutrient-permeable membrane 
technology. In general, cells are maintained in a small (15 ml) cultivation chamber (cell 
compartment) that is separated from a one litre nutrient supply compartment by a semi-
permeable membrane. Nutrients and other small molecules pass across the semi-permeable 
cellulose acetate membrane into the cell chamber. Cell-secreted products (e.g. antibodies with 
Mr~150kDa) with a molecular weight greater than 10kDa are retained in the cell compartment of 
the device. The moulded silicone membrane on the bottom of the device allows oxygen to reach 
the cells from underneath. The cells settle upon the silicone membrane at the bottom of the cell 
compartment, which provides direct access to oxygen and carbon dioxide gases that rapidly 
diffuse across the membrane. This approach leads to high cell concentrations within the small 
volume of medium in the cell compartment (Figure. 2.1 and 2.2). 
The CELLine flask can generate an average yield of 30-50mg of antibody every two-four weeks 
from cells adapted to low serum-containing medium.  
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Figure 2.1. Scheme of CELLine flask. Figure from www.BD 
 
 
Figure 2.2. CELLine flask. Figure from   
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2.2.1.1 Adaptation of hybridoma cells to low serum conditions. 
The use of a CELLine system requires that cells adapt to low serum culture medium. BD Cell 
Serum-Free MAb Medium is a synthetic medium that does not require high serum 
supplementation. In general, OKT3 hybridoma cells were grown in DMEM +10% foetal calf 
serum (FCS) for two weeks after bringing to culture. The cells were seeded into an adaptation 
culture vessel using a 3:1 mixture of BD Cell MAb Serum Free Medium to the pre-adaptation 
DMEM medium formulation. Then the cells were maintained for a week and split in the mixture 
when necessary.  
Slow continuous increase of BD Cell MAb Serum Free Medium content was performed over 6 
weeks. After this period cells were ready to grow in 100% BD Cell MAb Serum Free Medium 
containing 1.25% immunoglobulin (Ig)-low Serum. Importantly, a high cell density should be 
maintained throughout the process for successful adaptation.  
 
2.2.1.2 Antibody Production 
An adaptation procedure was followed to prepare cells for the use of the CELLine system. The 
nutrient and cell compartment medium was prewarmed to 37°C to prevent condensation and to 
eliminate significant temperature fluctuations inside the CELLine device. 
First, the nutrient compartment was prewet with 25ml of the medium to avoid damage of the 
membrane. Then the cells were resuspended in 15ml of BD Cell Serum-Free Medium, 
containing 1.25% Ig-low serum, at 2x106/ml and loaded to the cell compartment. The nutrient 
compartment was filled with one litre of serum free BD Cell MAb Medium.  
 
2.2.1.3 Antibody Harvest 
On day seven, cells with antibody-containing medium were collected from the cell compartment. 
The sample was centrifuged for 5min at 200xg. Antibody–containing supernatant was collected 
to a separate tube, 0.1% sodium azide was added as preservative and it was stored at +4°C. 
The CELLine device was reloaded with the cells resuspended in 15ml of BD Cell MAb medium 
containing 1.25% low-Ig serum. 
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2.2.1.4 Antibody purification 
For purification of antibodies isolation I used two kinds of affinity chromatography media. Protein 
A- and Protein G-Sepharoses have different IgG binding specificities, depending on the origin of 
the IgG. Compared to protein A, protein G binds more strongly to mono and polyclonal IgG, for 
example from cow or sheep. Furthermore, unlike protein A, protein G binds monoclonal rat IgG 
to which the OKT3 belongs. In that case, Protein A-Sepharose was applied for purification of the 
control antibodies (036 and 037 rabbit antisera) and Protein G-Sepharose for OKT3 IgG2a 
antibodies. 
 
2.2.1.5  OKT3 antibodies purification: Protein G-Sepharose 4 Fast Flow column. 
Prior to the affinity purification of OKT3 the supernatant was centrifuged (1000xg for 10minutes) 
and diluted with the equal volume of Binding buffer. A 5ml Protein G-Sepharose column was 
prepared according to the manufacturer‘s instruction. The column was equilibrated with 5 bed 
volumes of Binding buffer and the sample, diluted 1:1 in Binding buffer, applied to the column. 
Any large impurities were eliminated by filtration of sample through a 0.45μm syringe filter. The 
column was washed with 5 volume of Binding buffer. 
In the next step the antibodies were eluted with Elution buffer and 500μl samples were collected 
into 1.5ml tubes, containing 100μl of Neutralizing buffer. The column was regenerated with 
Binding buffer. 
 
Materials: 
Binding and washing buffer: 20mM Sodium Phosphate, pH 7.0 
Elution buffer: 0.1M glycine-HCl, pH 2.4 
Neutralizing buffer: 1M Tris-HCl, pH 9.0 
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2.2.2 Cell culture  
All procedures were carried out in a laminar flow class 2 tissue culture hood. Jurkat T cells and 
Raji B cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) FCS at 37oC in 
the atmosphere of 5% CO2. Cells were grown in tissue culture flasks until the adequate density 
(2-10 × 106 cells/ml) was reached. Cells were counted regularly using a haemocytometer.  
 
MRC5. HEK293A and MD-MBA-231 cells were cultured in DMEM medium supplemented with 
10% FCS, at 37oC in the atmosphere of 5% CO2. Cells were grown in flasks and multi-well 
dishes until 80% confluence was reached; they were then washed with PBS, treated with 
Trypsin-EDTA for 2 minutes to detach the cells, and then resuspended in growth medium and 
incubated as described above.  
2.2.3 Frozen storage of cells 
For long term storage of cells, these were harvested from a confluent 25cm2 T-flask and taken 
up in 3 ml of ice-cold ―Freezing medium‖ (FCS containing 10% (v/v) DMSO). The suspension 
was aliquoted into two cryotubes, placed in a neoLab-Freezing box Cryo-Safe (-1°, 120 mm Ø, 
86 mm high) to allow slow decrease of the temperature and incubated for 24 hours at -80°C 
freezer. Then the tubes were stored in liquid N2. 
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2.2.4 Cell transfection 
2.2.4.1 Transfection of HEK293 cells 
Lipofectamine 2000 transfection reagent (Invitrogen) was used for transfection of pHA-rSDC-4-
IRES-EGFP and pIRES2-EGFP plasmids into HEK293A cells. Transfection was performed on 
autoclaved coverslips in 24-well dishes. A day before the transfection, 2 × 105 cells per well 
were seeded in the antibiotic-free serum-containing medium in a 24-well dish. On the day of 
transfection, the medium was replaced with fresh medium followed by the addition of the 
transfection mixture. For each well, the transfection mixture was created by mixing 2.5µg of 
DNA construct diluted in 35µl of OptiMEM® medium and 1.2µl of Lipofectamine™ 2000 diluted 
in 35µl of OptiMEM® I Medium. Both solutions were incubated for 5 minutes at room 
temperature, then the diluted DNA was combined with the diluted Lipofectamine™ 2000 and 
incubated at room temperature for another 20 minutes to allow DNA-Lipofectamine™ 2000 
complexes, also called transfection mixture, formation. The transfection mixture was added 
directly to each well containing cells and mixed gently by rocking the dish back and forth. 
Samples were incubated for 4 hours at 37oC in a CO2 incubator. Then the medium was changed 
and the cells were used for the immunofluorescence 24 hours post-transfection.  
 
2.2.4.2 Transfection of Jurkat T cells 
First, the appropriate number of wells in a 24-well dish were filled with 0.5 ml of complete 
medium and pre-conditioned in the 5% CO2 incubator (37°C) for at least 15 minutes. 
Transfections of Jurkat T cells using pHA-rSDC-4-IRES EGFP, pHA-hSDC-4-IRES-EGFP and 
pIRES2-EGFP plasmids were performed using the electroporation technique called 
microporation (see section 3.2.1 for details). For microporation, were used per well of the 24-
well dish: 3g of pHA-rSDC-4-IRES-EGFP DNA, 4g of pHA-hSDC-4-IRES-EGFP DNA or 
0.1g of pIRES2-EGFP DNA in 10 µl of Buffer R supplied by the manufacturer (Invitrogen). The 
cells were first centrifuged at 800 rpm for 2min at room temperature, washed with PBS and 
resuspended in Solution R buffer by gentle pipetting to obtain a single cell suspension. The 
DNA was added and mixed by tapping of the tube with a finger. Such mixture was directly 
applied for the microporation in the supplied electroporation tip. Similarly, 2 x 106 cells, ten times 
larger amount of the DNA plasmid and 6-well dish containing 2 ml of pre-conditioned medium 
were used for the microporation of Jurkat T cells in the 100 µl electroporation tip. 
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The Microporator settings were optimised for 1400V, 10msec, 3pulses, independent of the 
electroporation sample size (see section 3.2.1.1 for details).  
 
2.2.5 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
10% sodium citrate venous blood was obtained from a donor, diluted 1:1 with serum-free RPMI 
1640 medium and gently layered on Ficoll-PaqueTM PLUS in the ratio1:2 (Ficoll:blood). After 
centrifugation at 1000rpm (no brakes) at room temperature for 30 minutes, the white, cloudy 
interface between the bottom Ficoll layer and upper RPMI layer was transferred to a new tube. 
Cells were washed twice with PBS. Samples were centrifuged after each wash at 800rpm at RT 
for 10 minutes. Pellets were resuspended in serum-containing RPMI-1640 medium, transferred 
to a 96-well plate and either left inactivated or a mix of superantigens (1µg/ml Staphylococcal 
enterotoxin SEE, 2µg/ml SEA, 2µg/ml SEB) in RPMI-1640 supplemented with 10% FCS was 
added to activate them. The cells were cultured at 37oC in the atmosphere of 5% CO2 for a 
week and flow cytometry analysis was performed each day. 
 
2.2.5.1 Isolation of CD4+ T cells  
The PBMCs were cultured for 4 days and T cells were isolated every day by negative selection 
using the Invitrogen Dynabeads® Untouched™ Human CD4+T Cell Isolation Kit. 1x107 cells 
were incubated with 100µl of Isolation Buffer (PBS + 2%FCS and 2mM EDTA) containing 20µl 
of heat activated FCS and 20µl of Antibody Mix for 20min at 4°C, then washed with 2ml of 
Isolation Buffer and centrifuged at 300xg for 8 min at 4°C . The Isolation Buffer and pre-washed 
Depletion MyOne Dynabeads were added to the washed cells and incubated for another 15 min 
at 24°C with gentle tilting and rotation. The beads were removed with a magnet. The 
supernatant was transferred to the new tube and cells were centrifuged for 10min at 300rpm. 
RNA extractions were performed from selected T cells followed by RT-PCR. 
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2.2.6 Molecular Biology Protocols 
A standard PCR reaction contained the following: 5l of 10X PCR buffer, 2.5mM dNTPs, 
10pmol of each primer (Forward and Reverse), 1 unit of Taq DNA polymerase (Invitrogen), 1-
5l of DNA (~500ng), made to 50l with sterile water. For reactions with more than 2 samples a 
master mix was prepared. 
2.2.6.1 DNA plasmid preparation  
2.2.6.1.1 Transformation of bacteria  
50 μl DH5α subcloning efficient cells were thawed on ice for 5 min, mixed with 2 μl plasmid DNA 
and incubated on ice for 30 minutes. The mixture was heat-shocked at 42°C for 45 seconds and 
placed on ice for another 2 minutes. 950 μl of the pre-heated SOC medium (Invitrogen) was 
added to the cells which were then incubated at 37°C for 1 hour with orbital shaking applied. 
Finally, 200 μl of the culture were plated on selective LB-agar Petri dishes (ø 9 cm) and placed 
at 37°C overnight.  
2.2.6.1.2 Plasmid purification  
Plasmids pHA-rSDC-4-IRES-EGFP, pHA-hSDC-4-IRES-EGFP and pIRES2-EGFP were purified 
using the EndoFree Plasmid Maxi kit (Qiagen Cat.No.12362). DNA concentration and purity 
were determined by measuring absorbance at 260 nm and 280 nm employing a Nanodrop ND-
1000 spectrophotometer. Purity was assessed by the A260/A280 ratio where ratios of 1.8-2.0 
were considered free of contaminants. The plasmids were sent to MWG Eurofins (Germany) for 
sequencing. 
 
2.2.6.2 RNA isolation and Reverse-Transcription PCR 
Total RNA was extracted from the isolated T cells using the Trizol® Reagent. Approximately 1 x 
107 of PBS-washed T cells were used for each individual extraction and the spin protocol for the 
RNA extraction was followed as provided by the manufacturer. Quantitation of RNA quality and 
concentration was carried out using 260nm absorbance analysis in a spectrophotometer and 
the RNA integrity was visualised on a 1% agarose gel.  
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Then the SuperScript® first strand for RT-PCR was used and the manufacturer‘s protocol was 
followed. Finally, the RT-PCR reaction consisted of 2.5l of cDNA, 5l of 10X Buffer, 1.5l of 
MgCl2, 1l of dNTPs (10mM), 0.5l primer (25pmol mix) and sterile water to a total of 50l. The 
cycles used were as for PCR reported in section 2.2.3.1. Primers were used as for PCR 
reactions. PCR for the human SDC-4 sequence was carried out with 2µl of cDNA and the 
following primers F (Forward) – CGAGAGACTGAGGTCATCGAC, R (Reverse) – 
GCGGTAGAACTCATTGGTGG (product of 453bp). Amplification was performed using the 
following protocol: 94oC – 2 minutes, 94oC – 50 seconds, 53oC – 50 seconds, 72oC – 6 minutes, 
repeated for 35 cycles. PCR was also carried out with GAPDH with 2µl of the RT-PCR reaction. 
These GAPDH primers were used as a control for the RT reaction and possible genomic 
contamination when used in the absence of an RT enzyme. The product amplification was 
analysed by 1% agarose gel electrophoresis (with 5l ethidium bromide (10mg/ml) per 50ml of 
gel) and a 1kb or more suitable ladder. 
 
2.2.6.3 SDS-PAGE  
Protein samples were separated by molecular weight using a Tris/glycine SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) system. The SDS binds to the proteins creating an uniform 
negative charge and the Electrode buffer permits the movement of current and thus the 
movement of charged proteins down the gel. Homemade gels were prepared using a Biorad 
mini gel system. 10-15% gels composed of running gel (250 mM Tris pH 8.8, 10-15% 
acrylamide-bisacrylamide mix (37.5:1) (BIORAD), 0.2% APS, 0.1% SDS, 0.082% TEMED) and 
4% stacking gel (158 mM Tris pH 6.8, 0.3% APS, 0.1% SDS, 0.15% TEMED). For each layer of 
the gels to set, a layer of propan-2-ol was poured on top and left at room temperature for 30 
minutes. Gels were cast between two glass plates (BioRad system) which were held together 
with clamps. Plastic combs were used to create the sample wells. After setting of the gels, the 
apparatus was assembled and the chambers filled with running buffer. 
All protein samples were prepared in NuPage LDS sample buffer (Invitrogen) with 12.5 mM DTT 
added. All samples were incubated at 95°C for 5 minutes prior to loading,  
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2.2.6.4 Western Blotting 
Proteins were transferred onto celulose membranes (pre-soaked in transfer buffer) using a 
semi-dry transfer system. Transfer buffer used was electrode buffer (25 mM Tris (pH 8.3), 192 
mM glycine and 1% SDS) . Transfer was run for 1 h 30 min at 1 mA/cm2 for home-made 0.75 
mm gels. After transfer, membranes were blocked in 5% filtered non-fat milk for 1 h at room 
temperature or overnight at 4C. Details of primary antibodies used are shown in Table 2.1.11. 
All antibody incubations were done for 1 h at room temperature. Secondary goat anti-mouse 
and goat anti-rabbit HRP-coupled antibodies (Southern Biotech) were used at  1:20,000 dilution. 
Washes after all antibody incubations were done in PBS-T 4-5×5 min. Bands were detected 
using ECL Plus Western blotting reagent (GE Healthcare) and light detection at 530 nm using 
an Ettan DIGE Imager (GE Healthcare). 
  
2.2.6.5 Proximal signalling analysis in conjugates 
Conjugates were prepared the same way as in section 1.2.6.3.1, but varying time of incubation 
at 37°C was applied: 2, 4 and 8 minutes. Conjugates were prepared with Raji B cells pre-loaded 
with SEE or not (for control). After the incubation and brief spin, 100μl of Cell lysis buffer 
(pervanadate and DTT were added at the latest possible point) were added to samples and 
these were left on ice for 40 minutes (lysis). The insoluble material was removed by a short 
centrifugation step of 3000g for 3 minutes at 4°C. 70µl from each sample were moved to a new 
Eppendorf tube, 30µl of 5x sample buffer (SB) buffer were added to each tube, the samples 
were boiled for 3min at 100°C and then equal volumes of samples were loaded to SDS-PAGE. 
The levels of Phosphotyrosine and α-Tubulin were then determined using Western blotting with 
specific antibodies. 
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2.2.7 Microscopy 
 
2.2.7.1 Preparation of Fixation solution 
4% paraformaldehyde (PFA) was prepared by adding 1g of PFA and 0.5g sucrose in 25ml of 
PBS and heated at 65°C for 5 minutes, then 400µl of 1M NaOH were added and heated at 65oC 
for 10 minutes. Finally, approximately 250µl of 1M HCl were added to adjust pH to 7.2.  
 
2.2.7.2 PLL-coated coverslip preparation 
The coverslips were washed with Piranha solution (30:70 (v/v) 30% H2O2 stock:95-98% H2SO4 
stock). The solution was prepared by gently mixing the H2SO4 with H2O2 and the coverslips 
were left in the solution for 15 minutes. Then the solution was removed and the coverslips were 
washed 10x with high quality water. Later, a 0.01% poly-L-lysine solution (0.1% stock) was 
added for 1h at RT, then removed and the coverslips dried at 65°C for 30 minutes. The 
coverslips were washed twice with PBS and water just before use. 
 
2.2.7.3 Preparation of coverslips with fixed cells  
Adherent HEK293A cells were cultured on coverslips in 24-well dishes overnight at 37oC with 
5% CO2 atmosphere after being sparsely plated. Cells were then treated with 4% PFA to fix the 
cells (500µl/well), then the fixation solution was aspirated and then the cells were washed twice 
with PBS+0.1M ammonium chloride and once with PBS only. 
 
2.2.7.3.1 Preparation of conjugates formed between Jurkat T cells and Raji B cells  
Raji B cells were counted and the appropriate volume was transferred to 15ml tubes, and 
pelleted for 5min at 1000rpm. Then the pellet was resuspended at 1x106 cells per ml in RPMI. 
SEE was added to a final concentration of 1µg/ml and the tube was incubated with the lid loose 
for 1h at 37°C, in a CO2 incubator. Meanwhile, the Jurkat T cells were counted (the same 
number of cells as for Raji cells), pelleted cells were washed with serum-free RPMI-1640 and 
resuspended in serum-free RPMI at the same concentration as Raji B cells.  
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At the end of the SEE incubation, the Raji cells were washed with serum-free RPMI and 
resuspended to 1x106 cells/ml. Then 200µl of Raji B cells, pre-loaded (or not) with SEE, were 
added to 200µl of Jurkat T cells in 5ml centrifugation tubes (Falcon) spun at RT for 1min at 
100xg and incubated without disturbing the pellet in a 37°C water bath for 5min. Then, 200µl of 
the supernatant from the top of the sample was taken off using a tipped pipette, then the pellet 
was broken up by pipetting up-down gently with a cut p20 pipette tip and a 50µl sample was 
transferred onto a 12mm round coverslip. The coverslips placed in a 24-well dish were floated 
on a 37°C water bath for 2min, then fixed with 500µl Fixation solution (containing 4% PFA) for 
20min at RT. 
 
2.2.7.4 Immunofluorescence 
After fixation, cells were washed twice with PBS + 0.1M ammonium chloride and once with PBS 
only. Then, 0.2% TritonX100 in PBS was added to samples and left for 8 minutes at RT to 
permeabilise the cells. The liquid was then aspirated and the cells were washed 3x with PBS, 
blocked with 5% BSA + 0.2% fish skin gelatine for 1h at RT and, after aspirating the liquid, the 
primary antibody was added to the sample at an appropriate concentration (as previously 
optimised) in 5% BSA/PBS and left for 1 hour at RT. After washing 10x by dipping the coverslip 
in a beaker containing PBS and once for 5min on a drop of PBS, the secondary antibody with 
an appropriate fluorophore was added at 1:200 in 5% BSA/PBS for 30 minutes at RT. Cells 
were then washed in a beaker with PBS as for primary antibody and twice on a drop of PBS. 
Finally, the sample was desalted by dipping in water and left to air dry for 5min. Coverslips were 
mounted onto slides using Prolong® Gold antifade reagent. 
 
2.2.7.5 Imaging 
For confocal imaging, the cells were imaged on an inverted laser scanning confocal 
fluorescence microscope (Zeiss LSM 510) using a 63X 1.2NA oil-immersion objective). For dual 
labelling experiments laser line 543nm (20%) was used for Alexa555 and filter BP560-615 was 
used to select the detection wavelength; laser line 633nm (20%) was used for Alexa633 and 
filter LP650 to select the detection wavelength. Finally, the images were analysed with ZEN 
2008 software by Carl Zeiss. 
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2.2.7.6  Live cell imaging 
On the day of the experiment, Raji B cells (APCs) were labelled with Orange cell tracker (2µl per 
1ml of resuspended cells; 1x106 cells per ml of serum-free RPMI-1640) for 30 min at 37°C, 
washed, resuspended in RPMI-1640 containing 10%FCS and loaded with SEE (1µg/ml) for 1h 
at 37°C. Afterwards, the cells were washed once with serum-free RPMI-1640 and resuspended 
to 0.5x106 cells per ml of serum–free and Phenol Red-free RPMI-1640. 200µl of Raji B cells  
were applied on the microscopy glass-bottomed MatTek dish (cat. P35G-0-20-C, 35mm, 20mm 
glass diameter). To reduce the mobility of the Raji B cells for imaging, they were left to settle 
and attach to the glass bottom of the dish for 2 minutes. Then, the medium was removed and 
300 µl of Jurkat T cells (0.5 × 106 cells per ml of Phenol Red-free RPMI-1640 containing 0.5% 
FCS) were added, followed by the immediate acquisition of the events. One frame every 10 sec 
was taken over a period of 30 minutes. The images were taken using an inverted epi-
fluorescence microscope Zeiss Axiovert 200M with a X20, PlanApo objective, Zeiss. Orange cell 
tracker labelled B cells were detected with 555 laser and transfected Jurkat T cells with 488 
laser.  
In next step the results were analysed with Definiens® software (Germany). All details and 
explanation of the steps are presented in Results - section 3.5.2.1. 
2.2.8 Flow Cytometry analysis 
2.2.8.1 Conjugates formation 
The conjugates were prepared the same way as described in section 2.2.7.3.1. The cells were 
fixed with Fix/Perm Kit (BD Biosciences) according to the manufacturer‘s recommendations or 
left unfixed. Unfixed cells were kept at 37°C till the measurement was performed using the 
LSRII flow cytometer. 
2.2.8.2 SDC-4 detection in T cells 
PBMC were selected from blood and either left unactivated or activated with a mix of 
superantigens (1µg/ml Staphylococus SEE, 2µg/ml SEA, 2µg/ml SEB). The mixtures were 
cultured in RPMI-1640 supplemented with 10% FCS at 37oC in the atmosphere of 5% CO2/95% 
air over a week. For each day the 96well plate was prepared with 20 wells containing 200µl of 
PBMCs suspention (1x106/ml). 
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Every day one plate with  the cells were first stained with primary conjugated antibodies to 
detect CD4+, CD25+. For detection of CD4+ T cells I used antiCD4–FITC conjugated Abs, for 
CD25+ T cells the antiCD25-APC conjugated Abs were used in concentration 10µg/ml. .  The 
cells were stained for 30min (10µl/well was used). Then the cells were washed twice with 100 µl 
PBS (3min spun, 500rpm) and either immediately stained for SDC-4 (for surface staining) or 
permabilized  with BD cytofix/cytoperm buffer (10µl per well) and then stained (for total staining)   
For SDC-4 detection the SDC-4-PE Abs were used in conc. 2µg per 1x106cells. The cells were 
stained for 30min and washed  twice with PBS as previously.  Measurement was done using a 
FACS Calibur flow cytometer.  In each measurement 50000 cells were acquired. All the data 
were analysed using FlowJo flow cytometry software. 
2.2.8.3 Proximal signalling analysis in conjugates 
Conjugates were prepared the same way as in section 2.2.7.3.1 but varying the time of 
incubation at 37°C, 2, 4 and 8 minutes. Conjugates were prepared with Raji B cells pre-loaded 
with SEE or not (for control). After the incubation and brief spin, 100μl of Cytoperm/Cytofix 
solution was added, incubated for 20min at 8°C, washed with TBS and stained with 4G10 Abs 
against proteins phosphorylated on tyrosine for 30min at RT. Then the cells were washed twice 
with TBS and secondary antibodies (anti mouse IgG2a Alexa555, Invitrogen) were applied for 
30 min. After that the cells were washed once again and the measurement was taken. 
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3 Results 
 
3.1 Detection of endogenous SDC-4 
SDC-4 has been reported to be expressed by resting and activated human T cells at different 
levels [142]. I verified the expression of SDC-4 in these cells as well as in Jurkat T cells, which I 
planned to use as model cells. Flow cytometry using commercial antibodies which were 
reported in similar studies [142, 165, 166] was employed for these experiments. 
 
In flow cytometry, the analysis is performed by passing hundreds of fluorescently-labelled cells 
per second through a laser beam and capturing the light that emerges from each cell as it 
passes through (Figure 3.1). As a cell passes through the laser beam, it refracts or scatters the 
light at all angles. Forward scatter counts (FSC) represent the amount of light that is scattered in 
the forward direction and is roughly proportional to the size of the cell. Light scattering 
measured from the side (SSC) is caused by the granularity and structural complexity inside the 
cell. The side-scattered light is focused through a lens system and collected by a detector 
usually located 90 degrees from the laser‘s path. The fluorescent light emitted by labelled cells 
travels along the same path as the SSC signal and is directed through a series of filters and 
mirrors, so that particular wavelength ranges are delivered to the appropriate detectors [167]. 
The obtained data can be plotted on two-dimensional dot plots or simple histograms and 
processed by analytical flow cytometry software (e.g. FlowJo, CellQuest, WinMDI). Regions on 
these plots can be sequentially separated, based on specific criteria, by creating a series of 
subset extractions, termed "gates." The gating is frequently done based on the levels of specific 
markers (e.g. anti-CD4 or anti-CD25 antibodies for T cells) which are fluorescently labelled and 
specifically bind cells. 
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Figure 3.1. A. Basic principle of the flow cytometry; B. Cell analysis using specific markers. 
Figure from www.microporator.com [168, 169]. 
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3.1.1 Detection SDC-4 with 5G9 antibodies by flow cytometry  
First, I examined the expression of SDC-4 in resting (naïve) and activated primary human T 
cells over a period of 5 days using flow cytometry and 5G9, an anti-human SDC-4 antibody 
(Santa Cruz Biotechnologies, Santa Cruz, USA), the most frequently used tool for SDC-4 
expression analysis found in the literature [142, 143, 165, 166]. A multicellular population of 
peripheral blood mononuclear cells (PBMCs) was used for T cell activation and expression 
profile experiments. For activation, PBMCs and a mixture of superantigens (SEA, SEB, SEE) 
were incubated in a 96-well U-bottom plate to best mimic the physiological situation where T 
cells are crowded in a limited space of the lymph nodes. 
In order to distinguish T cells within the mixed 
population, PBMCs were stained with fluorescently-
labelled anti-CD4 (FITC-conjugated), a marker of T 
cell subpopulation involved in humoral immune 
response, and anti-CD25 (APC-conjugated) for the 
selection of activated T cells. The expression of SDC-
4 was detected using the 5G9 anti-SDC-4 antibody 
(also directly PE-conjugated Figure 3.2 
CD4 and CD25 
CD4 is a co-receptor of T cell 
receptor (TCR) and it helps TCR 
during the activation of T cell 
following an interaction with 
APC. It directly interacts with 
MHC class II molecules on the 
surface of the APCs via its 
extracellular domain. 
CD25 (IL2Rα chain) expression is 
upregulated during the activation 
of T cell after the contact with 
APC presenting antigens or 
superantigens (see for more 
details Introduction). 
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Figure 3.2. Dot plots illustrating the selection of stimulated T cells after flow cytometry analysis. 
The individual dot plots depict: the size (FSC) and granularity (SSC) of the cells (A), specific 
selection of T cells by gating for the CD4-positive cells (B) and the gating for the CD25-positive 
activated CD4 T cells (C). The histogram shows the SDC-4 expression of activated T cells, 
control corresponds to unstained activated T cells (D). The presented data are for the fourth day 
of PBMCs stimulation. 
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Staining for SDC-4 was performed before or after fixation/permeabilisation of cells to acquire 
data for the surface as well as the total (including intracellular and surface) expression, 
respectively (Figure 3.2). I followed the expression profile of SDC-4 for stimulated T cells over 5 
days (Figure 3.3). The results indicate the increase of the SDC-4 expression level in course of 
time. In general, a higher SDC-4 expression was detected in activated T cells compared to their 
resting counterparts(ex vivo). At the surface protein level, SDC-4 expression was only slightly 
increased over the tested period (Figure 3.4 A) but the total expression increased more 
dramatically and reached the highest level approximately on day four (Figure 3.4 B). 
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Figure 3.3. Histograms of A surface and B total expression of SDC-4 in T cells stimulated (or 
not) for the indicated period of time – day 0 (ex vivo), day 1 and day 4. The PBMCs were 
stimulated with a mixture of superantigens and stained with antibodies against CD4 and CD25 
for the identification of activated T cells and PE-labelled 5G9 antibody for SDC-4 detection. 
Control corresponds to cells unstained with 5G9-PE antibody on day 0. The histograms are 
representative of 10 experiments. 50000 cells were analysed per measurement. 
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Figure 3.4. Surface and total expression of SDC-4 in stimulated primary human T cells. The 
PBMCs were stimulated with a mixture of superantigens and stained with anti-CD4_FITC 
antibodies against CD4 and anti-CD25-APC against CD25 for the identification of activated T 
cells. antiSDC-4-PE antibody (5G9-PE) were used to detect SDC-4. Control corresponds to 
cells not labelled with anti-SDC-4-PE antibodies. The graphs are representative of 10 
experiments. 50000 cells were acquired per measurement. 
 
The data presented on Figure 3.4 represent one of 10 experiments. Due to variation in results 
between the experiments I am not able to conclude on which day syndecans expression is the 
highest. It has been mentioned by Ariizumi group that they also noticed differences in SDC-4 
expression levels and time of the highest expression in the cells coming from different donors 
[141]. The reason for that can be that some donors already has quite a high level of activated T 
cells (e.g. after having cold).  
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The expression level of SDC-4 was also examined in Jurkat T cells using 5G9 and ab24511 
(rabbit anti-hSDC4 –intracellular domain) antibodies and flow cytometry since these cells were 
used as model T cells in my project. Results presented in Figure 3.5 and 3.6 indicate very low 
surface but detectable intracellular expression of SDC-4 in Jurkat T cells. 
 
Figure 3.5. Histograms of A) surface and B) total expression of SDC-4 in Jurkat T cells stained 
with PE-labelled 5G9 (anti-SDC-4) antibody. Control corresponds to unstained cells. 
 
Figure 3.6. Histograms of total expression of SDC-4 in Jurkat T cells stained with antibody (against 
intracellular part of SDC-4) ab24511 (anti-SDC-4 rabbit polyclonal, Abcam) and with secondary anti-
rabbit-Alexa555 antibodies. Control corresponds to the cells stained with secondary antibody only . 
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3.1.2 Detection of  SDC-4 with RT-PCR  
To check presence of SDC-4 I also performed RT-PCR. The PBMCs were isolated from blood 
and incubated with a mixture of superantigens. On days 0, 2 and 4 the samples were collected, 
the T cells were isolated, RNA prepared and RT-PCR was performed on day 4. The quality of 
RNA was checked on agarose gel and concentration was measured on Nanodrop. 
The results in Figure 3.7 show that there is SDC-4 weakly expressed in primary T cells on day 
4. Robust SDC-4 expression was detected in Jurkat and positive control MB-MDA-231 breast 
carcinoma cells. GAPDH was used as a positive control transcript for successful RT-PCR 
amplification; however, GAPDH mRNA was also undetectable on day 0 and was barely 
detectable on day 2. I did not detect SDC-4 on day 0 and 2 so I cannot unequivocally confirm 
the increase of SDC-4 level in activated T cells using this technique. Lack of results on days 0 
and 2 may be due to too low amount of DNA used or lack of my experience with the technique. 
However, because the ex vivo T cells are quiescent and have low metabolic activity it is 
probable that GAPDH, an enzyme involved in glycolysis and energy metabolism, is genuinely 
expressed at low levels and is only subsequently induced upon cell activation, becoming 
detectable by day 4. This makes it very difficult, and perhaps impossible, to choose an 
appropriate control transcript, as most genes will be downregulated in quiescent cells. 
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Figure 3.7. RT-PCR results for T cells day 0 (ex vivo), day 2 and day 4 of stimulated primary 
human T cell as well as HEK cells (negative control), MD-MBA-231 (positive control) and Jurkat 
T cells. GAPDH was used as a control of mRNA loading in the RT-PCR reaction. 
 
 
3.1.3 Summary 
The expression level of endogenous SDC-4 in human T cells is reported to be low and to 
increase following activation. Similarly, Jurkat T cells (my model cells) have low endogenous 
surface SDC-4 expression, which makes them more suitable for my model.  
Studying why SDC-4 is increased over time in activated T cells can bring some new information 
about IS formation and its stability. Unfortunately, a model system is needed for experiments 
studying the effect of increased SDC-4 expression – Jurkat T cells in our case - as the level of 
endogenous expression of T cells is too low. 
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3.2 Detection of exogenous SDC-4 in Jurkat T cells 
As shown in previous section the surface SDC-4 levels are very low in tested cells. Therefore, 
exogenous expression in a model system, Jurkat T cells, has been applied for further studies 
focused on the SDC-4 impact on the IS formation and stability. 
3.2.1 Jurkat T cell transfection optimisation 
Optimalisation of the transfection was essential step as numerous protocols for Jurkat T cell 
plasmid DNA transfection were reported in published works and on-line but only a handful were 
found to work outside the laboratory which presented the technique. Of those, two main 
systems were successfully used: viral transduction and electroporation. Since the first one 
requires cloning of genes into specialised vectors (plasmids) and work with viruses, I decided to 
focus on electroporation. Nucleofection, which refers to the electroporation technique 
established by AMAXA (version 2; currently Lonza, Germany), was previously successfully 
applied for DNA delivery to Jurkat T cells in our laboratory. However, the viability of transfected 
cells was low (~ 20-30%; M. Cebecauer, personal communication) even though 50-70% 
transfection efficiency could be achieved. Therefore, I decided to focus on a novel 
electroporation technology called microporation (Figure 3.8.) 
 
Figure 3.8. Microporator main device (1) with microporator pipette (2), pipette station (3), tips 
(4) and the solution kit (5). Figure from www.microporator.com [168]. 
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Microporation is a proprietary electroporation technology developed by NanoEnTek (South 
Korea), now commercially available from Life Technologies/Invitrogen under the commercial 
name Neon™. The majority of electroporation techniques employ plate-type electrodes and 
cuvette style chambers for the electric shock application. Microporation is unique in using a 
pipette tip with a needle-shaped electrode as an electroporation space (Figure 3.9.) 
 
 
 
 
Figure 3.9. (A) Cuvette chamber with plate-type electrodes; and (B) pipette tip with needle-
shaped electrode, as used in Microporation. Figure from www.microporator.com [168]. 
 
 
The advantage of using microporation with the tip-shaped electrode is in the generation of a 
more uniform electric field which minimises heat generation, metal ion dissolution, pH variation 
and oxidation, all of which are harmful events to the cell (probably causing reduced viability of 
the nucleofected cells using AMAXA system). Improved transfection efficiency and cell survival 
rate are benefits which made this technique my choice. 
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3.2.1.1 Microporator settings optimisation 
First, transfection efficiency and viability of the cells were tested for a number of settings 
recommended by the manufacturer, using the control pEGFP-N1 plasmid at a concentration of 
1µg per well (Table 3.1). The voltage, pulse width and pulse number can be varied. Flow 
cytometry was used for the viability and transfection efficiency analysis (see below for details of 
the examination). 
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Well # Pulse 
voltage (V) 
Pulse width 
(msec) 
Pulse number Transfection 
efficiency 
Viability 
1 control without application of the electric shock (microporation) 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
1400 
1500 
1600 
1700 
1100 
1200 
1300 
1450 
1000 
1200 
1100 
1200 
1300 
1400 
900 
1000 
1100 
1250 
1350 
1400 
20 
20 
20 
20 
30 
30 
30 
30 
40 
40 
20 
20 
20 
20 
30 
30 
30 
30 
30 
30 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
1 
1 
1 
High 
Low 
Low 
No 
Low 
Low 
Low 
Low 
No 
No 
Low 
High 
Low 
High 
Low 
Low 
Low 
High 
High 
High 
Good 
Good 
Poor 
Good 
Poor 
Poor 
Poor 
Poor 
Poor 
Poor 
Poor 
Poor 
Poor 
Good 
Poor 
Poor 
Poor 
Poor 
Poor 
Good 
 
Table 3.1. The instrument settings optimisation tested for transfection of Jurkat T cells using 
pEGFP-N1 plasmid. Transfection efficiency and viability of the cells are shown for the indicated 
settings. The results presented in last two columns stand for transfection efficiency: No ≤20%,  
20%<Low ≤ 50%, High > 50% and viability: Poor ≤ 50% and Good > 50%. 
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In my study, the viability of the cells was analysed using SSC and FSC. Healthy, viable cells 
were gated first (Figure 3.10). In the next step, the transfected cells were analysed and 
compared with untransfected ones. The same gating was applied for all samples. Correct gating 
is based on the type of cells and experience. 
 
 
 
Figure 3.10. Jurkat T cells transfected with pEGFP-N1 plasmid (1µg/well) were analysed for the 
transfection efficiency using selected settings of the microporator. Flow cytometry was used for 
cell viability (FCS/SSC) analysis. Representative dot plots are shown for untransfected and 
selected conditions of microporation with the highest (80%) and the lowest (10%) viability of 
successfully transfected Jurkat T cells. Each dot in the graph corresponds to an individual cell. 
10000 cells were analysed per sample. 
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The transfection efficiency was measured by the fluorescent light detector and the data are 
presented the form of a histogram. The efficiency of the transfection (percentage of successfully 
transfected Jurkat T cells) was achieved by range gating, which means that a subset of the 
cells, which has higher fluorescence emission than untransfected cells, are counted as positive 
counts (transfected) (Figure 3.11).  
 
 
Figure 3.11. Jurkat T cells transfected with pEGFP-N1 plasmid (1µg/well) were analysed for the 
transfection efficiency using selected settings of the microporator. Flow cytometry was used for 
the cellular EGFP expression analysis. Histogram showing the level of expression of EGFP for 
untransfected (black line) and selected the most (red line – 72%) and least (blue line) 
successfully transfected Jurkat T cells. Untransfected cells were treated similarly to all 
transfected samples except for the electric shock for the electroporation. The transfection 
efficiency was based on gating by marker M1, which measures all the positively transfected 
(EGFP-positive) cells. The highest transfection in this experiment corresponds to settings 
1400V/30msec/1pulse and the lowest transfection of Jurkat T cells corresponds to settings 
1450V/30msec/1pulse presented in Table 3.1. 
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In summary, Figure 3.10 shows representative dot plots of the untransfected and exemplars of 
the most and least successfully transfected Jurkat T cells. Each dot in the graph corresponds to 
an individual cell. These representative results indicate that the transfection settings highly 
influence the viability of the cells. Figure 3.11 shows the histogram of the EGFP level of 
expression for the untransfected and selected most and least successfully transfected Jurkat T 
cells. Untransfected cells were treated similarly to all other (transfected) samples except for the 
electric shock for electroporation. In general, all microporator settings resulted in a reduced 
viability but at different levels of transfection efficiency. 
The data presented in Table 3.2 summarise the results for settings selected in Table 3.1 (wells 
number #2, 15 and 21) and their more subtle modifications (+/- 50V of the applied pulse 
voltage). The results expressed in red bold again indicate the highest viability and transfection 
efficiency - setting 1400V/30msec/1pulse; the lowest viability and transfection – setting 
1450V/30msec/1pulse are select in blue bold. The results acquired for untransfected cells are 
shown for comparison.  
Settings 
(V/msec/pulses)  
EGFP viability (%) / 
transfection efficiency (%) 
untransfected 82/1  
1400/20/1 
1450/20/1 
1500/20/1 
1350/30/1 
1400/30/1 
1450/30/1 
1350/20/2 
1400/20/2 
1450/20/2 
29/45 
46/56 
54/68 
44/66 
46/72 
17/38 
41/68 
39/66 
31/63 
 
Table 3.2. The viability and transfection efficiency was determined for Jurkat T cells transfected 
with pEGFP-N1 plasmid using indicated microporator settings. First column corresponds to the 
individual setting (pulse voltage (V)/pulse width (msec)/pulse number). Second column 
represents the viability (%)/ transfection efficiency (%) for every setting tested. 
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By fine tuning of the instrument settings I managed to optimise the conditions for 1400V-pulse 
voltage, 30msec-pulse width, 1 pulse which was my choice at this stage of the work as I 
achieved results of ~70% transfection efficiency and a approximately 50% viable Jurkat T cells 
using these values for microporation. 
At a later stage of the project, Invitrogen acquired the system from the microporator inventor, 
performed intense evaluation of the technique and suggested some critical improvements for 
customers, and have now launched the technology to the world-wide market under the name, 
"Neon™ Transfection System". I therefore decided to set up a new optimisation experiment 
using settings based on my previous experience and compared these to the values 
recommended by Invitrogen researchers. A fine tuning (increase and decrease in voltage by 
25V) was employed during this optimisation step. Again, the EGFP encoding plasmid was 
employed for the transfection optimisation. Results are presented in Table 3.3. 
Settings  
(V/msec/pulses) 
EGFP viability (%) / 
transfection efficiency (%)  
 Control 93/2  
1375/30/1 
1400/30/1 
1425/30/1 
1300/10/3 
1325/10/3 
1350/10/3 
1375/10/3 
1400/10/3 
1425/10/3  
90/40 
90/55 
84/40 
94/21 
94/21 
94/24 
95/37 
95/68  
94/35  
 
Table 3.3. The viability and transfection efficiency was determined for Jurkat T cells transfected 
with the pEGFP-N1 plasmid (at concentration 1µg per well) using my previously established 
optimal settings-1400V/30msec/1pulse and the ones suggested by Invitrogen 
(1400V/10msec/3pulses). I achieved the best results - shown in bold red. 
 
Applying the Invitrogen-suggested settings (1400V/10msec/3 pulses), a better viability (95%) 
and good transfection efficiency (68%) was achieved. Therefore, these settings were applied for 
the following experiments. 
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3.2.1.2  Plasmid DNA concentration optimisation 
3.2.1.2.1 EGFP- and rat SDC-4-encoding 
plasmids 
In addition to the instrument settings, DNA 
plasmid concentration is a sensitive parameter 
influencing the transfection efficiency and cell 
viability after electroporation. I used pEGFP-N1 
as a standard testing DNA but used a plasmid 
encoding HA-tagged rat (r) SDC-4 in the 
concentration set up analysis due to uneven 
behaviour of different plasmids in such technique. The EGFP expression level was again used 
for the transfection efficiency determination since the pHA-rSDC-4-IRES-EGFP plasmid 
encodes enhanced green fluorescent protein (EGFP) downstream of the internal ribosomal 
entry site (IRES). This EGFP fluorescence was also used for the regular testing of the 
transfection efficiency using flow cytometry or the identification of transfected Jurkat T cells in 
microscopy. 
In next step, I optimised the concentration for each plasmid separately to make the transfection 
efficiency and viability for both plasmids as similar as possible. I compared the transfection 
efficiency of pHA-rSDC-4-IRES-EGFP plasmid with our standard pEGFP-N1 plasmid in Jurkat T 
cells. As shown in the Table 3.4, the EGFP expression efficiency is significantly higher for the 
control pEGFP-N1 plasmid compared to pHA-rSDC-4-IRES-EGFP. The transfection efficiency 
was optimised based on the EGFP expression, which was higher in case of pEGFP-N1 plasmid 
(~4700 base pairs), possibly as it is smaller than pHA-rSDC-4-IRES-EGFP (~6300 bp) plasmid.  
 
 
 
 
 
 
 
 
Internal ribosomal entry site 
(IRES) 
An internal ribosome entry site (IRES), 
is a nucleotide sequence that allows 
for translation initiation in the middle 
of a messenger RNA (mRNA) sequence 
as a part of the complex process of 
protein synthesis. 
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Settings 
(V/msec/pulses) 
pHA-rSDC-4-IRES-EGFP (1µg/well) 
viability (% )/ transfection  (%) 
pEGFP-N1 (1µg/well) 
Viability (%) / transfection  (%) 
1400/30/1 48/26 62/51 
 
Table 3.4. The viability and transfection efficiency were determined for Jurkat T cells transfected 
with either pHA-rSDC-4-IRES-EGFP plasmid or pEGFP-N1 plasmid (both at a concentration of 
1µg per well) using settings 1400V/30msec/1pulse. 
 
 
 
Later, Jurkat T cells were transfected either with pHA-rSDC-4-IRES-EGFP plasmid or pEGFP-
N1 plasmid using two different concentrations based on previous results. Applied microporator 
settings were 1400V/30msec/1pulse since these were the selected best conditions at this stage 
of the project. 
 
 
Table 3.5 shows the results for Jurkat T cells transfected either with pHA-rSDC-4-IRES-EGFP 
plasmid in concentrations 1µg/well and 4µg/well, or pEGFP-N1 used in concentrations: 
0.1µg/well and 0.05µg/well. Using the same settings of the microporator for both plasmids 
results in very different expression efficiency, therefore the pEGFP-N1 plasmid concentration 
was lowered in order to get similar transfection efficiency for both plasmids. 
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Table 3.5. The viability and transfection efficiency was determined for Jurkat T cells transfected 
with pHA-rSDC-4-IRES-EGFP or pEGFP-N1 plasmids using indicated concentrations and my 
previously determined optimal settings -1400V/30msec/1pulse. The data in bold red indicate the 
most comparable results of the transfection efficiency and viability for both plasmids. 
 
 
 
Figure 3.12 presents the viability (A) dot plots and transfection efficiency (B) histogram for the 
results achieved using optimised concentration (Table 3.5) of plasmids and the previously 
optimized microporator settings 1400V/30msec/1pulse. 
Concentration pHA-rSDC-4-IRES-EGFP 
viability (%) / transfection (%)  
pEGFP-N1  
viability (%) / transfection (%)  
Control 88/1 87/1 
1 µg/well 
4 µg/well  
 
31/38 
40/42 
 
 
0.10 µg/well 
0.05 µg/well 
 48/32 
44/20 
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Figure 3.12. (A) Representative dot plots with indicated viability (%) for Jurkat T cells, 
untransfected and transfected with pEGFP-N1 or pHA-SDC-4-IRES-EGFP plasmids using 
selected 1400V/30msec/1pulse condition of microporation. Each dot in the graph corresponds 
to an individual cell. 10000 cells were analysed per measurement. (B) Histogram showing the 
results achieved with optimised concentration of plasmids in order to attain as similar as 
possible level of expression of EGFP for both plasmids. Positive expression was determined 
based on the EGFP expression encoded by the plasmids (marker M1). 
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Plasmid concentrations were optimised for 1400V/30msec/1pulse since these were the selected 
best settings at this stage of the project. The most similar expression efficiency was achieved 
using 4 µg/well of pHA-rSDC-4-IRES-EGFP and 0.1µg/well of pEGFP-N1plasmid and the above 
mentioned microporator settings. 
 
After getting better results of the viability and transfection with pEGFP-N1 plasmid for the 
Invitrogen suggested settings (Section 3.2.1.1), the previously optimised plasmid concentrations 
were tested using the settings of 1400V/10msec/3pulses. The results are presented in Table 
3.6. 
 
Settings 
(V/msec/pulses) 
pHA-rSDC-4-IRES-EGFP 
viability (%)/ transfection (%) 
pEGFP-N1  
viability (%)/ transfection (%) 
1400/10/3 81/63 79/78 
 
Table 3.6. The viability and transfection efficiency was determined for Jurkat T cells transfected 
with pHA-rSDC-4-IRES-EGFP or pEGFP-N1 plasmid using concentrations optimised earlier in 
the project: 4µg/well of HA-rSDC-4-pIRES-EGFP and 0.1µg/well of pEGFP-N1; and Invitrogen-
suggested and optimised settings of1400V/10msec/3pulses. 
 
3.2.1.2.2 The plasmid encoding human SDC-4  
In a later stage of the project, I received a plasmid encoding HA-tagged human (h) SDC-4 in the 
pMEXneo vector (pMEXneo-HA-hSDC-4). This vector does not encode EGFP. Therefore, anti-
HA tag antibody (HA.11 from Covance) was used for the immunofluorescent detection of the 
exogenous protein in transfected Jurkat T cells. As for the rSDC-4-encoding plasmid, DNA 
concentration optimisation of the transfection efficiency was performed for pMEXneo-HA-hSDC-
4 plasmid (data not shown). 
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I required EGFP expression driven from the same plasmid for the subsequent experiments 
Therefore, the insert (DNA fragment encoding HA-tagged hSDC-4) was subcloned into the 
pIRES-EGFP vector (kindly performed by Dr. Marek Cebecauer). This plasmid was used in the 
functional studies (such as live cell imaging) as I was more interested in the effect of hSDC-4 in 
human T cells. I was, therefore, able to base the transfection efficiency control on the EGFP 
expression. Also, at that point of the project I changed control plasmid from pEGFP-N1 to 
pIRES2-EGFP to apply more similar vector for the functional assays. Both of these plasmids 
encode the same protein EGFP, but pIRES2-EGFP is expressing from the IRES, the same way 
as the plasmids encoding human (and rat) SDC-4. I used Invitrogen-suggested settings of 
1400V/10msec/3 pulses and the concentration of 4µg/µl of pHA-hSDC-4-IRES-EGFP and 
0.1µg/µl of pIRES2-EGFP. I got similar expression and viability levels using these conditions 
(presented in Figure 3.13). These conditions were used for all following experiments. 
 
 
 
 
Figure 3.13. Histogram showing the level of expression of EGFP from the pHA-hSDC-4-IRES-
EGFP and control pIRES2-EGFP plasmids in Jurkat T cells using microporator settings of 1400 
V/10 msec/3 pulses, and concentration of 4µg/well pHA-hSDC-4-IRES-EGFP and 0.1µg/well 
pIRES2-EGFP. 
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3.3 Cellular localisation of SDC-4 
3.3.1 Using 5G9 antibody 
The next step of my study was to determine the spatial localisation of SDC-4 in T cells. First, I 
used 5G9 antibody (Santa Cruz Biotechnologies, Santa Cruz, USA) recognising an epitope in 
the extracellular part of SDC-4 known from the literature [148, 166]. I tested the antibody on 
cells which are known to express high levels of SDC-4 – human breast cancer cells MD-MBA-
231 (positive control), and on cells which were reported to express minimal levels of SDC-4 - 
human embryonic kidney 293 cells (HEK293; negative control) (Figure 3.14). 
 
Figure 3.14. Images of MD-MBA-231 (positive control) and HEK293 cells (negative control) 
stained with 5G9 antibody against the extracellular part of SDC-4 (cyan) followed by secondary 
Abs mouse anti-IgG2a Alexa 555 and with phalloidin Alexa 647 (for fibrillar actin; magenta). 
Brightfield (BF) shows the shape of cells. 
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Intense spot-like signals were observed on images of positive control cells (MD-MBA-231), 
which can correspond to the accumulation of SDC-4 in focal adhesions in agreement with 
previously published data [4]. The dramatic difference between positive and negative control 
cells (Figure 3.14) indicated that this antibody can be applied for the immunofluorescence 
studies performed on conjugates formed between Jurkat T and Raji B cells (functioning here as 
APCs) (Figure 3.15). Conjugation takes place after mixing Raji B cells (loaded in advance with 
superantigens) with Jurkat T cells and incubation at 37°C for 5 minutes. 
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Figure 3.15. Images of conjugates formed by Raji B cell and Jurkat T cells transfected with A) 
pHA-rSDC-4- IRES-EGFP or B) control pIRES2-EGFP plasmid and stained with 5G9 antibodies 
against the extracellular part of SDC-4 , followed by secondary Abs mouse anti-IgG2a Alexa633 
(cyan). Typical Lck localisation(cells stained with anti-Lck abs, followed by secondary mouse 
anti-IgG2aAbs) indicates the formation of productive IS (magenta). GFP indicates the 
transfection efficiency in Jurkat T cells. Brightfield (BF) shows the shape of cells. Example 
results of 20 conjugates analysed for each transfection. 
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The observed results do not detect any presence of SDC-4 in the conjugating cells. One 
possible reason why there was no signal detected is because the 5G9 antibody was not 
sensitive enough for this technique. 
3.3.2 Using ab24511 antibody 
The ab24511, a commercially (Abcam, Cambridge, UK) available rabbit polyclonal antibody, 
was generated against a peptide derived from the intracellular part of human SDC-4. Again, I 
tested ab24511 first on cells which were reported to express, or not, high levels of SDC-4, MD-
MBA-231 and HEK293 respectively (Figure 3.16). My results exhibited similar distribution of  
SDC-4 in positive cells (MD-MBA-231) to the one which was previously observed using 5G9 
antibody, but with reduced background. Negative control indicates the specificity of the staining. 
In order to better test the specificity of the ab24511 antibody, I decided to transfect HEK293 with 
HA-rSDC-4-encoding plasmid (Figure 3.17). 
 
 
Figure 3.16. Images of MD-MBA-231 (positive control) and HEK293 (negative control) cells 
labelled with ab24511 antibody against the intracellular part of SDC-4 followed by staining with 
secondary Ab anti-rabbit-Alexa555 (cyan)and with phalloidin-Alexa647 for fibrillar actin; 
(magenta staining). BF shows the cells in bright field. 
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Figure 3.17. HEK293 cells transfected with pHA-rSDC-4-IRES-EGFP plasmid to check the 
selectivity of ab24511 antibody for SDC- 4 (followed by secondary anti- rabbit-Alexa 555 
antybodies) (B) (cyan). The phalloidin Alexa 647 staining of actin fibres 
(A)(magenta).Transfection efficiency control – EGFP (C), Margegd image (D) of A and B. BF – 
cells in the bright field (E). Exo SDC-4 = exogenous SDC-4.  
 
The results suggest high specificity of the ab24511 antibody for SDC-4 since the intense signal 
was detected only in the cells transfected with the pHA-rSDC-4-IRES-EGFP plasmid. These 
cells were determined based on the GFP fluorescence, which was expressed from the IRES of 
the plasmid. 
Next, these antibodies were used for the analysis of the SDC-4 localisation in conjugates 
formed between Jurkat T cells, transfected with the pHA-rSDC-4-IRES-EGFP or pIRES2-EGFP 
plasmids, and APC (Raji cells) (Figure 3.18). 
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Figure 3.18. Images of conjugates formed between: (A) Jurkat T cells transfected with pHA-
rSDC-4-IRES-EGFP or (B) pIRES2-EGFP plasmid, and Raji B cells – stained with ab24511 
antibody against the intracellular part of SDC-4 and secondary anti-rabbit-Alexa 555 antibodies. 
GFP serves to control for expression level. BF shows the cells in bright field. 
 
Non-homogeneous fluorescence signal (spots) for SDC-4 staining in tested cells shows similar 
pattern to the results which were achieved for the positive control represented by MD-MBA-231 
cells (Figure 3.14 and 3.16) or HEK293 cells transfected with pHA-rSDC-4-IRES-EGFP (Figure 
3.17). More intense signal for SDC-4 was observed for Jurkat T cells transfected with pHA-
rSDC-4-IRES-EGFP (Figure 3.18A) in comparison to Jurkat T cells transfected with pIRES2-
EGFP (Figure 3.18B). The strong accumulation of SDC-4 in the pHA-rSDC-4-pIRES-EGFP-
transfected T cell indicates the presence of SDC-4 in Jurkat T cells. Unfortunately, there was 
strong signal detected in Raji cells conjugating with the transfected and untransfected Jurkat T 
cells. The high level of endogenous SDC-4 expression in Raji cells made it impossible to 
specifically localise SDC-4 in Jurkat-Raji conjugates. Therefore, I looked for another strategy of 
exogenous SDC-4 localisation in Jurkat T cells. 
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3.3.3 Using HA tag antibody 
I took the advantage of the presence of a short peptide 
tag in the constructs encoding SDC-4 (e.g. pHA-rSDC-4-
IRES-EGFP) and employed antibody against HA tag 
(HA.11, Covance) for the localisation of the exogenous 
SDC-4 in Jurkat T cells) (Figure 3.20). The addition of 
the HA tag to the protein of interest allows the detection 
of SDC-4 with an antibody against the HA sequence 
using immunofluorescence methods. 
 
 
Later in the project, I acquired the human (h) HA-SDC-4 
protein-encoding plasmid (pMEXneo-HA-hSDC-4) (a 
kind gift from Prof. John Couchman‘s lab, University of Copenhagen) and I successfully 
generated Jurkat T cells stably transfected with human pHA-SDC-4. For detection of the 
positively transfected cells I used Abs against HA tag (Figure 3.19) and Flow cytometry 
technique first. Stable over-expression of SDC-4 unfortunately resulted in the down-regulation of 
the surface TCRs so these cells were not suitable for my subsequent purposes. No change in 
TCR surface expression was observed in Jurkat T cells transiently transfected with plasmid 
encoding human SDC-4 (Figure 3.19C).  
HA is an epitope tag 
(YPYDVPDYA) derived from the 
haemagglutinin molecule of 
the influenza virus. It can be 
used in many different assays 
that require recognition by an 
antibody and there is no 
useful antibody against the 
studied protein or, as in our 
case, none of the available 
antibodies gives satisfactory 
results. 
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Figure 3.19. CD3 downregulation in Jurkat T cells stably transfected with h-SDC-4. (A) gating 
for living cells; (B) gating for SDC-4 positive Jurkat T cells – the gating was done based on HA 
tag presence (detected with HA1.1 Abs and secondary anti murine IgG1-Alexa488; (C) 
histogram of CD3ε detection in stably and transiently transfected Jurkat T cells with pHA-hSDC-
4-IRES-EGFP. The cells were stained with OKT3 Abs and anti-murine IgG2a-Alexa555. Control 
histogram for transiently transfected Jurkat stained with secondary Abs only overlapped the 
histogram result for stably transfected stained Jurkat T cell.  
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In next step the insert (DNA fragment encoding HA-hSDC-4) was subcloned into pIRES-EGFP 
vector (kindly performed by Marek Cebecauer). Thus, in the next step, I transfected Jurkat T 
cells with pHA-hSDC-4-IRES-EGFP and pIRES2-EGFP plasmids, and stained the cells with 
antibody against HA tag for immunofluorescence microscopy (Figure 3.20). These results for 
the first time demonstrate exogenous SDC-4 localisation in (Jurkat) T cells. SDC-4 was 
accumulated in the plasma membrane and also in vesicles in the cell. Also, SDC-4 was not 
distributed equally throughout the whole plasma membrane, but rather accumulated in certain 
areas of this structure. 
 
 
Figure 3.20. Images of Jurkat T cells transfected with (A) pHA-hSDC-4-IRES-EGFP or (B) 
pIRES2-EGFP plasmids and stained with the antibody against HA tag (HA.11) present on the N-
terminus of SDC-4 and secondary anti-mIgG1-Alexa633 Ab. GFP images show the expression 
level. BF images show the cells in bright field. Representative image of 10 cells from 2 
experiments is shown. 
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I also employed the antibody against the HA tag to localise SDC-4 in the conjugates formed 
between transfected Jurkat T cells and Raji B cells (APC) (Figure 3.21A and B). The results 
display relatively intense and specific signal for HA tag in the conjugates formed between Jurkat 
T cells transfected with pHA-hSDC-4-IRES-EGFP plasmid and Raji cells loaded with SEE. Only 
a very weak signal for HA tag was detected in Jurkat T cells transfected with pIRES2-EGFP 
plasmid conjugated with Raji B cells loaded with SEE. These data demonstrated the 
accumulation of SDC-4 in perinuclear membranous area of the cell and near the contact site 
(the IS) of the conjugating cells. This is in good agreement with the results achieved when using 
ab24511. Thus, the immunofluorescence microscopy allowed me to confirm the specificity of the 
antibodies and the correlation of the HA tag and SDC-4 antibody signals within Jurkat T cells. 
Such results also allowed me to use these antibodies for the co-localisation studies (the 
following section). 
 
 
Figure 3.21. Representative images of HA-tagged hSDC-4 in conjugates formed between Raji 
B cells (APC) and Jurkat T cells transfected with A) pHA-hSDC4-IRES-EGFP and B) pIRES2-
EGFP and stained with the antibody against HA tag (HA.11) present on the N-terminus of SDC-
4 and secondary anti-mIgG1-Alexa633 Ab. GFP shows the expression level. BF shows the cells 
in bright field. Representative image of 20 conjugates from 3 experiments is shown. 
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3.3.4 Summary 
In this section I presented the approaches used to demonstrate SDC-4 localisation in 
unconjugated and conjugated Jurkat T cells. The data were acquired using untransfected cells, 
as well as those transfected with rat or human SDC-4 fused to HA tag and cloned into pIRES-
EGFP plasmid. The lack of good direct antibodies against SDC-4 made it more difficult to 
determine the exact localisation of the native protein. 
The first antibody tested – 5G9 from Santa Cruz Biotechnologies, Ltd. - exhibited poor 
specificity. The other antibody tested – ab24511 from AbCam, Ltd. – gave specific results but, 
unfortunately, intense signal for endogenous SDC-4 expressed in Raji B cells (functioning as 
APC in my assays) was also detected. This disabled the spatial detection of endogenous SDC-4 
in T cells, the cells of my primary interest. In my last approach, the antibody against HA tag, 
Covance, Ltd. (genetically fused to the N-terminus of rat and human SDC-4) allowed me to 
demonstrate more precisely the localisation of SDC-4 within unconjugated and conjugated 
transfected Jurkat T cells.  
No conclusive SDC-4 localisation, but rather highly varying pattern, has been detected in 
conjugates formed between Jurkat T and superantigen-loaded Raji B cells (APCs). SDC-4 in 
transfected T cells was detected in the plasma membrane, intracellular vesicles, uropod or 
perinuclear membraneous recycling compartment as presented in my work. 
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3.4 Co-localisation of SDC-4 in human T cells 
 
After studies on SDC-4 localisation I hypothesised that the presence of SDC-4 may not be 
random and may have an impact on conjugates formation, as well as cellular function and 
stability of the IS. In the next step I tried to determine the localisation of SDC-4 in relation to the 
receptors and signalling molecules which are either known to interact with the SDC-4 molecule, 
such as fibronectin, or potentially are involved in T cell activation (TCR/CD3 complex and 
proteins phosphorylated on tyrosine(s) - results shown in next section).  
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3.4.1 With TCR/CD3 complex 
The results from the localisation of SDC-4 show different accumulation of this molecule in T 
cells. The prevalent pattern was the confinement to the perinuclear recycling membranous 
compartment, which is situated just below the contact side of the T cell and APC in the 
productive synapses. TCR/CD3 complex and Lck kinase were shown previously to accumulate 
in the IS but also in this compartment during or after the activation of T cells [93]. Therefore, I 
first tested the co-localisation of the SDC-4 with TCR/CD3 receptors. 
I transfected the T cells with pHA-hSDC-4-IRES-EGFP plasmid and formed conjugates with Raji 
B cells pre-loaded with superantigen. Then I performed immunostaining with OKT3 antibody 
against CD3ε chain (description in the Introduction section) and HA.11 against HA tag to 
localise SDC-4. Results are presented in Figure 3.22. The results showed no co-localisation for 
SDC-4 and TCR/CD3 complex. 
 
 
 
Figure 3.22. Representative image of one out of 20 conjugates formed by Jurkat T cells 
transfected with pHA-hSDC-4-IRES-EGFP and SAg-loaded Raji B cells, stained with antibodies 
against CD3ε chain  (secondary Abs mIgG2a-Alexa555(magenta)) and HA tag for the SDC-4 
localisation (secondary Abs mIgG1-Alexa633 (cyan). GFP (green) shows the level of 
transfection. Example result of 20 conjugates analysed from 3 different experiments.  
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3.4.2 Proteins phosphorylated on tyrosine 
In next step, I checked the co-localisation of SDC-4 with signal coming from the proteins 
phosphorylated on tyrosine(s). Tyrosine phosphorylation is one of the earliest events in the T 
cell activation and is involved in the initiation the signalling cascades. Jurkat T cells transfected 
with pHA-hSDC-4-IRES-EGFP plasmid formed conjugates with Raji B cells and were stained 
with 4G10 (Upstate Biotechnology) antibody against phosphorylated tyrosine (pY) and HA.11 
antibody against HA tag to localise SDC-4. Results are presented in Figure 3.23. They showed 
little (probably accidental) or no co-localisation for SDC-4 and proteins phosphorylated on 
tyrosine(s). 
 
 
 
Figure 3.23. The images of the representative conjugate (1 out of 20 analysed) formed of Jurkat 
T cells transfected with pHA-hSDC-4-pIRES-EGFP and Raji B cells, and stained with 4G10 
antibody against phosphorylated tyrosine(s)(secondary mIgG2a-Alexa555) (cyan) and HA tag 
for the SDC-4 localisation (secondary mIgG1-Alexa633) (magenta). GFP (green) shows the 
level of transfection. Example result of 20 conjugates analysed from 3 different experiments. 
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3.4.3 Fibronectin 
In addition to the molecules involved in T cell activation I tested whether SDC-4 can interact or 
co-localise with its well documented binding partner, fibronectin. Since no data were available 
about fibronectin and T cells, I was interested in the presence of this extracellular matrix 
molecule in the IS or at the surface of T cells and APCs. I first checked the specificity of the 
rabbit antiserum against fibronectin (kind gift from Prof. John Couchman). I used MRC5 human 
skin fibroblast cells as a positive control and MD-MBA-231 cells as a negative control for the 
immunofluorescence studies of the fibronectin (Figure 3.24). The typical fibrillar fibronectin 
staining localised at attachment sides of the actin fibres (stained with phalloidin) to the surface 
of the coverslip. The difference in signal between positive and negative samples confirmed the 
specificity of the antiserum against fibronectin. 
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Figure 3.24. Images of (A) MRC5 (positive control) and (B) MD-MBA-231 cells (negative 
control) stained with antibodies against fibronectin (cyan), (secondary anti-rabbit-Alexa555) and 
phalloidin- Alexa647 (fibrillar actin staining; magenta). 
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After confirming that the antibodies are specific to fibronectin, I investigated the presence of 
fibronectin in conjugates formed between Jurkat T cells and Raji B cells (APC) (Figure 3.25). 
Immunofluorescence results demonstrated that there is no detectable fibronectin present in the 
IS or at the surface of Jurkat T and Raji B cells, despite the cells being grown in fibronectin-rich 
serum. 
 
 
Figure 3.25. Representative images of the conjugate formed between a Jurkat T cell and a Raji 
B cell (APC) (preloaded with superantigen; SEE) labelled with the antiserum against fibronectin 
(secondary antibodies anti-rabbit-Alexa555) (cyan) and Lck 3A5 (secondary anti-mIgG2b-
Alexa633) (magenta). BF shows the cells in the bright field.  
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3.4.4 Summary 
The results showed no co-localisation between SDC-4 and TCR/CD3 complex or proteins 
phosphorylated tyrosine(s) in conjugated Jurkat T cells and Raji B cells. Such results do not 
support SDC-4 having a direct role in the TCR signalling, but rather it may play a role in the 
regulation of T cell properties (most probably adhesion), similar to its function demonstrated in 
motile fibroblasts. I did not detect any presence of fibronectin, the known ligand of SDC-4, in the 
IS or at the surface of T cells and APCs. Nevertheless, I observed anecdotally that Jurkat T 
cells transfected with SDC-4 appeared to be less likely to form conjugates with Raji B cells 
loaded with superantigen). Thus, in the next step, I decided to quantitate the number of 
conjugates formed by Jurkat T cells transfected with either pHA-rSDC-4-IRES-EGFP or 
pIRES2-EGFP and Raji B cells pre-loaded or not with superantigen. 
 
3.5 Conjugate formation analysis 
3.5.1 Using dual-cell flow cytometry  
The dual-cell flow cytometry technique was employed for a quantitative analysis of T cells 
forming conjugates with antigen-presenting cells (APCs). Flow cytometry application for this 
kind of analysis is rarely used as it requires expensive equipment and careful control of 
conditions.  
Using two cell trackers with different fluorescence properties I demonstrated the formation of 
conjugates between Jurkat T and Raji B cells (APCs) (Figure 3.26). In this experiment I labelled 
Jurkat T cells with Green cell tracker (excitation-492nm/emission-517nm) and Raji B cells with 
Orange cell tracker (excitation-541nm/emission-565nm). Raji cells were loaded with SEE or not, 
then Jurkat and Raji cells were mixed, allowed to interact by mild centrifugation for 1 min, 
conjugated by incubation for 5 min at 37°C and immediately analysed using flow cytometry 
(details in Materials and Methods section). The cells were kept at approximately 37°C 
throughout the whole measurement. The results were quantitated using flow cytometry 
analytical software FlowJo (Tree Star, North America). (Figure 3.26). 
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Figure 3.26. Dot-plots illustrating the procedure for flow cytometry data analysis: (A) Jurkat T 
cells (bottom right quarter), SAg-loaded Raji B cells (top left quarter) and conjugated Jurkat/Raji 
cells (top right quarter). (B) Quantitated numbers (% of total cells) for Jurkat T cells, Raji B cells 
and conjugates (indicated by red square) using FlowJo analytical software. 
 
Using dual-cell flow cytometry, I successfully demonstrated the formation of conjugates between 
Jurkat T and SAg-loaded Raji B cells (APCs). I assumed that the number of T-B conjugates 
reflects the frequency of synapse formation between T cells and APCs under the tested 
conditions. On the other hand, very similar numbers of conjugates formed in the presence and 
absence of superantigen showed that conjugates are independently formed and are probably 
more likely to be formed by the cells which were briefly centrifuged (in order to help conjugates 
formation – see Discussion for more details).  
Since I aimed to study the influence of SDC-4 on the T cell activation process, in the next step, 
Jurkat T cells were transiently transfected with pHA-rSDC-4-IRES-EGFP (label: Jurkat SDC-4 T 
cells) or pIRES2-EGFP (label: Jurkat EGFP T cells) plasmids, Raji B cells were labelled with 
Orange cell tracker and the experiment was repeated using the same conditions as for the 
untransfected cells. Here, the GFP fluorescence encoded into the plasmid was used instead of 
Green cell tracker, used in set-up experiments, for the identification of Jurkat T cells - Figure 
3.27).  
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The experiment was repeated three times and the quantitation is presented in Figure 3.28. I 
observed only a minor decrease in number of conjugates formed by Jurkat T cells transiently 
transfected to overexpress SDC-4 compared to T cells transfected with EGFP only. 
Interestingly, slight decrease in conjugates formation was observed in the presence, but also in 
the absence, of the superantigen on the APCs. 
Moreover, the number of conjugates formed between transfected Jurkat T cells and Raji B cells 
was lower in comparison to the conjugates formed by untransfected T cells and Raji B cells. The 
possible explanation for this phenomenon is that this may be a side effect of the microporation 
which, similar to the other electroporation techniques, influences the cell membranes. 
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Figure 3.27. Illustrative dot-plots showing A) a gating for unconjugated transfected Jurkat T 
cells (bottom right corner), Raji B cells (loaded with Sag) (top left corner) and untransfected 
Jurkat T cells (left bottom corner) as well as conjugated transfected Jurkat (either with SDC-4 or 
EGFP only)/Raji cells (top right corner); and for B) Jurkat T cells transfected with pHA-rSDC-4-
IRES-EGFP and Raji B cells and C) Jurkat T cells transfected with pIRES2-EGFP and Raji B 
cells with quantitated number of conjugates (indicated in red). The quantisation was performed 
using FlowJo software.50000 cells were acquired for each conditions. 
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Figure 3.28. Quantitation of the dual-cell flow cytometry analysis of the conjugates formed by: 
Jurkat T and Raji B cells (J/R); Jurkat T cells transfected with pIRES2-EGFP and Raji B cells 
(JEGFP/R) and Jurkat T cells transfected with pHA-rSDC-4-IRES-EGFP and Raji B cells 
(JSDC-4/R). SEE +/- corresponds to the presence or absence of SEE superantigen on the 
surface of Raji B cells. SD were calculated from 3 experiments. 
 
 
The dual-cell flow cytometry technique is highly dependent on the conditions during the 
experiment. I discovered that a small change in temperature during the experiment dramatically 
influenced the results (see relatively high SDs). Moreover, this technique does not allow the 
differentiation between poorly conjugated Jurkat and Raji cells, compared to those forming the 
mature synapse (see the following section). Therefore, live cell imaging was employed to better 
characterise the effect of SDC-4 on the T cell activation. 
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3.5.2 Using live cell imaging  
In my last approach, I employed live cell microscopy to image the cells when forming 
conjugates. The advantage of this technique is that it enables to partially mimic the physiological 
conditions which happen during the immune response. Moreover, as conjugate formation 
between the T cells and APCs is a fast process, with this approach I was able to monitor the 
first tens of seconds and minutes after the contact between the cells. None of the previously 
used techniques in this project was able to follow the shape changes of the T cell. Also,  the 
analysis of the data let me quantitate a number of cells and conjugates to increase the 
probability to detect a more subtle effect of SDC-4 on conjugates formation and/or morphology 
of T cells. 
3.5.2.1 Image analysis using Definiens ruleset  
The day before each experiment Jurkat T cells were transiently transfected with pHA-hSDC-4-
IRES-EGFP or pIRES2-EGFP (used here as a control – mock transfection) using the 
microporator and the conditions optimised before (see section ‗SDC-4 detection‘ for details). 
The transfection efficiency was regularly tested by flow cytometry. Representative results are 
presented in Figure 3.29 
 
Figure 3.29. Representative results of transient transfection efficiency for Jurkat T cells 
transfected with pHA-hSDC-4pIRES-EGFP or pIRES2-EGFP plasmids measured by flow 
cytometry. The cells were always tested on the day of each live cell imaging experiment. 
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On the day of the experiment, Raji B cells (APCs), labelled with Orange cell tracker for their 
easy identification, were loaded with superantigen (SEE) for 1h at 37°C, washed and applied 
onto the microscopy glass-bottom MatTek dish as described in Materials and Methods, (section 
2.2.7.6). To reduce the mobility of the APCs for imaging, they were loaded in a serum-free 
medium and left for 2 minutes to settle the cells down at the bottom of the dish. Then, the 
medium was removed and the T cells were added, followed by the immediate acquisition of the 
events on a CCD camera of the wide-field microscope.  
 
Overall, we performed over 50 experiments, which correspond to the 50 individual days when 
transfection was completed (the day before) and cells (including various conditions and DNA 
constructs) were tested. The first 15 experiments were performed to optimise the conditions of 
the experiments, as there was no literature describing this kind of approach available. After 
testing different microscopy dishes, microscope settings, optimising the number of cells applied 
on the dish, and acquisition time and frequency, I found satisfactory conditions. Total acquisition 
time was 30 minutes with each frame collected every 10 seconds (Movies 1 and 2; in the 
attached DVDs).  
 
Each day, 8 to 12 datasets were acquired (4 to 6 for Jurkat T cells transfected with SDC-4-
encoding plasmid and equal number for EGFP only plasmid). This gave me over 500 datasets 
in total for the analysis. 
  
Movie 1. Live cell imaging data of conjugates formed between Jurkat T cells transfected with 
pIRES2-EGFP plasmid and Raji B cells.  
Movie 2. Live cell imaging data of conjugates formed between Jurkat T cells transfected with 
pHA-hSDC-4-IRES2-EGFP plasmid and Raji B cells.  
In both movies-Orange cells- Raji B cells are stained with Orange cell tracer; Green cells-
Jurkat T cells are transfected with pIRES2-EGFP (movie 1) or pHA-hSDC-4-EGFP (movie 2). 
Grey cells –untransfected Jurkat T cells. 
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In next step, the results were analysed using Definiens® software (Germany), which allowed us 
to quantitate the number of individual cells (T and B cells separately), as well as the conjugates 
formed. Moreover, the shape (morphology) analysis was enabled after advanced tuning of the 
analytical approach which was facilitated by the increased number of datasets acquired and 
analysed using its various versions. (Movies 3 and 4; in the attached DVDs presents the 
Definiens analysis of Movies 1 and 2 )  
 
 
 
The ruleset (Attachment 1) was kindly created and provided by Dr. Martin Spitaler (the manager 
of the FILM Imaging Facility of the Imperial College London), but I was involved in the tuning 
process by applying the ruleset in progress on the representative datasets and during 
discussions about their improvement. 
Analysis using Definiens® software was performed in five different layers of segmentation 
(Figure 3.30 A) and as a final output yielded the number of individual Raji B cells (APCs), 
number of T cells present and the number of T cells forming synapses per frame. Each layer 
corresponds to different parameter which let to detect T cell, detect B cells, detect distal and 
proximal synapses and finally the conjugated T cells forming IS. The final analysis (shown at 
movies 3 and 4) is compensation of all layers analysis performed according to designed  ruleset 
(figure 3.30 B.  
 
Movie 3. Live cell imaging Definiens data analysis of conjugates formed between Jurkat T 
cells transfected with pIRES2-EGFP plasmid and Raji B cells. Raw data presented at Movie 
1.  
Movie 4. Live cell imaging Definiens data analysis of conjugates formed between Jurkat T 
cells transfected with pHA-hSDC-4-IRES2-EGFP plasmid and Raji B cells. Raw data presented 
at Movie 2. 
In both movies-Blue cells- Raji B cells are stained with Orange cell tracer; Red cells-Jurkat T 
cells are transfected with pIRES2-EGFP (movie 3) or pHA-hSDC-4-IRES32-EGFP (movie 4). 
Yellow cells –Jurkat T cells detected as the ones forming synapses. 
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A. 
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B. 
 
Figure 3.30. Definiens software performs (A) analysis in five different layers of segmentation for 
each frame (created by Dr. M. Spitaler). Different levels of segmentation are illustrated here. 
The important information can be obtained at all levels of the segmentation; (B) scheme of 
ruleset map of the Definiens analysis for each frame of each movie. 
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The optimisation of the ruleset for Definiens software was a long and complicated process, and 
different approaches must be tested. Originally, the relative border of the T cell to Raji cell was 
the only condition required, but it generated a number of false positive signals for cells which 
were just overlapping each other and not forming real synapses (conjugates). To solve this 
problem, Martin Spitaler brought the idea to define the proximal and distal synapses and apply 
the ratio between these two values as another condition for the IS analysis, as the proximal 
synapse should be always larger than the distal one in the proper IS. The ‗proximal‘ and ‗distal‘ 
synapses are defined based on the relative distance from the Raji cell (Figure 3.31). At the end, 
the detection of T cells forming synapses was based on two major conditions which need to be 
met. First of all, there has to be a large contact area relative to the total  T cell border between 
neighbouring T and B cells (within a range of 10-15%) and the area of the proximal synapse has 
to be ~25-30% larger than of the distal one. 
 
 
Figure 3.31. Examples of the proximal and distal synapses determination in (A) Jurkat T cell 
forming a true IS and (B) Jurkat T cell just non-specifically touching Raji B cells (APC). 
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Time-lapse results from the individual imaging experiments are presented on the graph plot in 
terms of absolute (Figure 3.32A) and relative numbers (Figure 3.32B). Unfortunately, the 
number of Jurkat T cells expressing EGFP from the pIRES2-EGFP plasmid was always higher 
than for those transfected with pHA-hSDC-4-IRES-EGFP plasmid. Therefore, instead of the 
absolute number of Jurkat T cells conjugating with Raji B cells, I used relative number of the 
cells, i.e. percentage of transfected T cells forming conjugates with the APCs, to describe 
quantitatively the capacity of Jurkat T cells to form the IS. 
 
Figure 3.32. Ilustrative graphs for (A) number of Jurkat T cells conjugating with Raji B cells and 
(B) the percentage of transfected Jurkat T cells conjugating with Raji B cells – an individual 
experiment is shown (see Figure 32 for a more global picture). Each frame was acquired every 
10 seconds and the whole acquisition was taken over 30 minutes. 
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The quantitative analysis was performed for all (fifteen) individual experiments (different 
transfections; experimental days) which, in total, resulted in 40 datasets for each, control EGFP 
only and SDC-4-transfected, cells. The average time-lapse values for all the data are presented 
on the graph in Figure 3.33. Large error bars and little difference between individual values of 
global conjugates formation per frame do not support any difference in the capacity of Jurkat T 
cells to form conjugates after the transfection either with pHA-SDC-4-IRES-EGFP or pIRES2-
EGFP plasmids. 
 
 
Figure 3.33. Graph summarising the average percentage of T cells forming IS with SEE-loaded 
Raji B cells. The values are per frame and x-axis indicates the frame number. Acquisition was 
set at 6 frames per minute. Red line corresponds to the cells transfected with the pHA-hSDC-4-
IRES-EGFP (SDC-4) and blue line to the cells transfected with pRES2-EGFP (EGFP) plasmid. 
SDs were calculated from 40 datasets for every transfection. 
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At first, I was disappointed by the fact I was unable to quantitate a difference between two sets 
of cells, a difference which had appeared evident by visual observation. Nevertheless, I 
hypothesised that more detailed analysis of the movies might reveal a difference in the shape of 
T cells forming IS, when transfected with the two different plasmids. In my next attempt I 
focused on the frame-by-frame digital image analysis of factors such as: asymmetry, border 
index, compactness, elliptic fit, roundness, border length, area, relative border of T cell to B cell 
and the ratio of the border of the T cell to its area. Movies 6 to 8 (in the attached DVDs) show 
examples of data acquired. The BF is turned off to better present the shape changes. 
 
 
 
For the advanced analysis, we selected only frames 30, 60 and 180, corresponding to 5, 10 and 
20 minutes from the beginning of the movie (the addition of T cells to the Raji B cells), and 
performed the test over ~40 movies for each, Jurkat T cells transfected with pIRES2-GFP and 
pHA-hSDC-4-IRES-GFP plasmids. The data presented in Figure 3.34 do not examine T cells 
which have not been identified as forming conjugates. Analysis only of T cells forming 
conjugates with Raji B cells should be valid since the percentage of conjugating T cells was 
similar for samples expressing EGFP only and those expressing SDC-4 (Figure 3.32). 
Movie 5. Live cell imaging data analysis of conjugates formed between Jurkat T cells 
transfected with pIRES2-EGFP plasmid and Raji B cells – example 1.  
Movie 6. Live cell imaging data analysis of conjugates formed between Jurkat T cells 
transfected with pIRES2-EGFP plasmid and Raji B cells – example 2.  
Movie 7. Live cell imaging data of conjugates formed between Jurkat T cells transfected 
with pHA-hSDC-4-IRES2-EGFP plasmid and Raji B cells – example 1. 
 Movie 8. Live cell imaging data of conjugates formed between Jurkat T cells transfected 
with pHA-hSDC-4-IRES2-EGFP plasmid and Raji B cells – example 2. 
In both movies-orange cells- Raji B cells are stained with Orange cell tracer; Green cells-
Jurkat T cells are transfected with pIRES2-EGFP (movies 5 and6) or pHA-hSDC-4-IRES-EGFP 
(movies 7 and 8). Brigthfield was turned off to beter show the shape changes of the T cells. 
The movies represent two different experiments for two different transfection with each 
plasmid. 
130 
 
Figure 3.34. The analysis of asymmetry (A), border index (B), compactness (C), elliptic fit (D) 
roundness (E), border length (F), area (G), relative border of T cell to B cell (H) and the ratio 
between the border and area of the T cell (I). Frames 30, 60 and 180 from ~40 movies of Jurkat 
T cells transfected with pIRES2-EGFP or pHA-hSDC-4-IRES-GFP plasmids have been 
examined. Error bars were calculated as the error from the average value. 
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The T cell morphology analysis was 
performed with automatically calculated by 
software parameters like asymmetry ect. The 
results confirmed the asymmetric character of 
Jurkat T cells transfected with pIRES-EGFP 
(EGFP only control), but less pronounced 
asymmetry for Jurkat T cells transfected with 
pHA-hSDC-4-IRES-EGFP (SDC-4) (Figure 
3.34). Compactness, relative border of the T 
cell to B cell and the ratio between border and 
area of the T cells are the parameters which 
show the biggest differences between control 
samples and those transfected with SDC-4, 
but only at frame 60. At the beginning (frame 
30) and end of the analysis (frame 180) these 
parameters are almost the same. This is in 
agreement with the visual observations that 
after the first big engulfing step (big increase 
in compactness and roundness for EGFP at 
frames 60), in the next step cells forming 
functional IS with APC acquire a more round 
shape again. Similarly, the relative border of T 
cell to B cell and the ratio of the T cell border 
to its area are lower for the SDC4-transfected 
cells, which confirms the observation that 
SDC-4 over-expressing Jurkat T cells do not 
intensely engulf B cells, but still form 
conjugates. Such data also indicate that the 
presence of SDC-4 on the surface of T cells 
allows contact formation between T cells and 
APC but somehow reduces their capacity to 
expand the contact area (see Discussion for more details).  
  
Asymmetry, Border index, 
Compactness, Elliptic fit, and 
Roundness of the object 
Asymmetry - describes the 
relative length of an object, 
compared to a regular polygon. 
An ellipse is approximated 
around the object, which can 
be expressed by the ratio of 
the length of its minor and 
major axes. 
Border index- describes how 
jagged an image object is; the 
smallest rectangle enclosing the 
image is created and the index is 
calculated as the ratio between 
the border lengths of the image 
object and the smallest enclosing 
rectangle. 
Compactness - describes how 
compact an image object is 
and is a product of the length 
and the width, divided by the 
number of pixels. 
Elliptic fit – describes how well an 
image object fits into an ellipse of 
similar size and proportions. 
Roundness - describes how 
similar the object is to an 
ellipse and is calculated by the 
difference of the enclosing 
ellipse and the enclosed one. 
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Roundness and Elliptic fit of SDC-4-overexpressing T cells show only minor differences 
between the T cells expressing SDC-4-EGFPand EGFP only. 
Parameters like Asymmetry, Border index, Border line and Area of the T cell are generally 
higher for pIRES-EGFP transfected T cells, but show almost the same alteration over the time.  
 
3.5.3 Summary 
Live cell imaging application presented above is a powerful technique which can bring a lot of 
information and some explanations to the current knowledge of the IS formation. Such an 
approach for the analysis of the IS formation brings the possibility of acquiring large datasets 
and makes the technique highly reliable. The Achilles‘ heel of this technique is the data 
analysis. I did not get a conclusive answer about the stability or speed of the IS formation by 
global image analysis. On the other hand, the changes in the shape of the IS for Jurkat T cells 
expressing EGFP only are significantly more pronounced  than those for SDC-4-overexpressing 
Jurkat T cells. Moreover the effect can be analysed in big number of cells in this approach.  
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3.6 T cell proximal signalling analysis 
 
A slight delay in the conjugates formation has been observed for Jurkat T cells transfected with 
pHA-hSDC-4-IRES-EGFP plasmid compared to their pIRES-EGFP plasmid transfected 
counterparts (see Figures 3.32 and 3.33). I, therefore, experimentally verified if there are any 
differences in proximal signalling events using biochemical (immunoblotting) and cell biology 
(flow cytometry) assays. I was unable to detect these signalling events (e.g. calcium 
mobilisation) using our live cell imaging system mainly because during the first two or three 
minutes of imaging, the period when such signalling events are most active, the acquisition was 
disturbed by the landing of T cells and the flow of the medium.  
3.6.1 Immunoblotting 
Immunoblotting assay was performed on conjugates formed between Jurkat T cells transfected 
with pHA-hSDC-4-IRES-EGFP or pIRES-EGFP plasmid and Raji B cells. T cells were 
transfected a day before the experiment, washed and mixed with Raji B cells pre-loaded with 
SEE. The mix was briefly spun, incubated at 37°C for 2, 8 and 20 minutes and lysed with Cell 
lysis buffer. Then the samples were subjected to 12% SDS-PAGE gel and transferred onto a 
nitrocellulose membrane, which was probed with 4G10 Ab against proteins phosphorylated on 
tyrosine and HRP-conjugated anti-mouse secondary antibody. Then the Abs were stripped and 
the membrane was reprobed with Ab against α-tubulin to control for equal sample loading. The 
signal was analysed and processed using ImageQuantTL software. Results presented in Figure 
3.35 and Table 3.7 show that very early signalling events produce  weaker phosphotyrosine 
signal for the conjugates formed by Jurkat T cells transfected to overexpress SDC-4 (and SEE 
pre-loaded Raji B cells) in comparison to the conjugates formed by Jurkat T cells transfected to 
express EGFP only. The most dramatic difference was observed for bands which should 
represent phosphorylated LAT, Src-family kinases (Lck) and ZAP-70 kinase (Table 3.7). 
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Figure 3.35. Conjugates between Jurkat T cells transfected with either pHA-SDC-4-IRES-EGFP 
(J_SDC4) or pIRES-EGFP (J_EGFP) plasmids and SEE-loaded Raji B cells were formed using 
varying incubation times (2, 8 and 20 minutes), lysed, subjected to 12% SDS-PAGE and 
immunoblotted. The membrane was probed with 4G10 Ab against proteins phosphorylated on 
tyrosines. Some bands (e.g. LAT, Lck, and ZAP-70) are labeled to indicate specific signalling 
molecules based on the experience from previous experiments; A.I.Magee and M.Cebecauer, 
personal communication). The membrane was then stripped and reprobed with Ab against α-
Tubulin to control the loading of the samples on the gel. Example result is shown of three similar 
experiments.  
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Table 3.7. Quantitation of Western Blotting bands (fold increase of signal and digital counts) for 
TCR signaling effector molecules ZAP70, Lck, LAT. Digital counts are presented also for the 
control of the loading α-Tubulin. Digital counts were calculated using ImageQuantTL software. 
Some bands are not detected for unconjugated Jurkat and Raji B cells - used as controls (-) ; 
half of the volume used for conjugated cells was loaded for unconjugated Jurkat and Raji 
controls.  
 
3.6.2 Flow cytometry  
The proximal signalling events were also investigated using flow cytometry and 4G10 Ab 
against proteins phosphorylated on tyrosines. The results (Figure 3.36) are in good agreement 
with the immunoblotting data described in the previous section, i.e. the early signalling events 
were delayed in conjugates formed by Jurkat T cells transfected with SDC-4-encoding plasmid 
and SEE-loaded Raji B cells in comparison to the conjugates formed by Jurkat T cells 
expressing only EGFP. There was no detectable phosphotyrosine signal in conjugates formed 
by Jurkat T cells overexpressing SDC-4 after 2 min of incubation, but the signal became 
stronger after 8 min of the incubation with Raji B cells pre-loaded with the superantigen. 
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Figure 3.36. The conjugates formed by Jurkat T cells overexpressing SDC-4 and SEE-loaded 
Raji B cells (SDC-4) and Jurkat T cells expressing only EGFP and SEE-loaded Raji B cells 
(EGFP). The cells were incubated for 2 (A) or 8 (B) minutes to form conjugates, fixed, 
permeabilised, washed and stained with 4G10 Ab against proteins phosphorylated on tyrosines 
(pY). Representative data are shown of 5 independent experiments.  
 
3.6.3 Summary 
T cell proximal signalling analysis using immunoblotting and flow cytometry techniques 
demonstrates that early signalling events in the IS formed between SDC-4-transfected Jurkat T 
cells and SEE-loaded Raji B cells are delayed in comparison with Jurkat T cells expressing 
EGFP alone. The differences are noticeable especially for 2min timepoint, interestingly for the 
8min timepoint the values are going up and stay high even for 20min timepoint, which in case 
for control conjugates goes down. It surely proofs the delay in signalling. 
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4 General Summary and Discussion 
  
The human immune system has been intensely studied over many years but a number of 
questions stay unanswered. A hot topic related to the function of T lymphocytes, one of the key 
cells of the immune system [68], is a better understanding of the properties and functions of the 
IS [66, 88, 105, 106, 108, 113, 170] formed between T cells and APCs. The structure and 
general function of the IS are well described [75, 104, 106], but new results are opening new 
questions and new techniques make it possible to study the IS in more details. That means, 
many facets of the IS structure and function require further experimental studies. Moreover, 
there are many aspects of the IS which can be studied. For example, one can focus on its 
formation, stability [108], or signalling events generated by the engagement of TCR [76, 97, 
118]. On the other hand, a number of unpredicted proteins which may appear in the IS only 
temporarily, and their function, could turn out to be crucial for the proper in vivo function of the 
IS formed between T cells and APCs.  
 
4.1 Summary of the results 
I hypothesised that one such protein can be SDC-4. Its tightly regulated expression level in 
human naive and activated T cells was published recently [142, 143] and I was able to confirm 
this observation (see section ‗SDC-4 detection‘). SDC-4 expression is upregulated by the 
activation of T cells. What does this mean? Can SDC-4 help to organise the IS or, in opposite, it 
can inhibit the IS formation and regulate the detachment of the T cell from APC after the 
essential recognition of the antigen period is over and not required anymore, i.e. be involved in 
down-regulating the T cell-APC interaction? 
Low levels of endogenous SDC-4 expression in human naive T cells and the sensitivity of these 
primary cells to handling, as well as their small size for imaging, made it difficult to monitor SDC-
4 localisation and function in these cells. Therefore, I had to find another model cell for my 
studies. The cells of choice were human Jurkat T cells, derived from an acute T cell leukaemia. 
The level of their endogenous SDC-4 expression is very low, so they are more similar to the 
resting T cells. In order to see the effect of increased SDC-4 expression I decided to transfect 
these cells with exogenous SDC-4. Transfection of Jurkat T cells is an inefficient process when 
using plasmids.  
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Viral vectors were successfully applied for the transfection of these cells by other groups. In 
consultation with my supervisors, I decided to avoid work with these complex genetic tools and 
focused on optimisation of the settings for the microporator (a novel version of electroporation). 
A careful and time-consuming optimisation process, including determination of the best 
concentration for individual plasmids, resulted in satisfactory results. During this process, I 
discovered that longer than 24h culture of the cells after transfection lowered their viability. In 
addition, I successfully generated Jurkat T cells stably transfected with human SDC-4, but this 
approach unfortunately resulted in the down-regulation of the surface TCRs so these cells were 
not suitable for my purpose. No change in TCR surface expression was observed in Jurkat T 
cells transiently transfected with plasmid encoding human SDC-4 (see 3.3.3 section in Results). 
Possible explanation for that may be that as SDC-4 expression increases over the time, the 
activity of PKCα becomes deregulated [61] which can cause the down-regulation of the TCR in 
stably transfected Jurkat T cells [171]. 
 
Jurkat T and Raji B cells forming conjugates in the presence or absence of antigen were 
selected as an experimental system for the functional assays. As an antigen, SEE superantigen 
was used for the pre-loading of Raji B cells. Efficient formation of conjugates and of the stable 
IS was observed for untransfected and EGFP-transfected Jurkat T cells in the presence of 
antigen-loaded Raji B cells. The advantage of the system is that it mimics well the native 
situation of T cells searching for antigen presented by APCs (e.g. dendritic cells).  
 
SDC-4 is intensely studied in migrating fibroblast [19] but little is known about its function in T 
cells and especially, according to my knowledge, in the formation and stability of the IS [172]. 
Therefore, I have focused on the process of T cell conjugation with the APC employing a 
number of imaging techniques. I investigated the localisation and effect of SDC-4 in the IS 
formed by Jurkat T cells transfected with plasmids encoding SDC-4 and Raji B cells (APC) 
presenting (or not) the antigen. I managed to detect a low level of exogenous SDC-4 in Jurkat T 
cells as well as in conjugates formed by these cells with Raji B cells by confocal microscopy 
(section ‗Localisation of SDC-4‘). Rather random localisation of SDC-4 in the membranes of 
individual (unconjugated) Jurkat T cells was observed, but also of those forming conjugates with 
Raji B cells. I also tested the co-localisation of the proteoglycan with its well-described ligand 
(fibronectin) and proteins of the TCR/CD3 complex, as well as effector proteins phosphorylated 
on tyrosine (section ‗Co-localisation of SDC-4 with receptors). I did not find any specific co-
localisation with these examined proteins.  
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SDC-4 was previously demonstrated to regulate the interaction of eukaryotic cells with the ECM 
and neighbouring cells via adhesion [173, 174]. Therefore, my primary interest became the 
quantitation of conjugates formed by Jurkat T cells transfected to overexpress SDC-4 with 
APCs, in comparison to Jurkat T cells expressing EGFP only. Such experiments should provide 
information on the role of SDC-4 in this process. Using the EGFP expressing Jurkat T cells as a 
control allowed me to eliminate the effect of the transfection in data analysis as it was involved 
in both cases. 
The first technique used for conjugates quantitation was flow cytometry as I assumed that the 
number of T-B conjugates reflects the frequency of synapse formation between T cells and 
APCs under the tested conditions. The results presented in the section 3.5.1 show a certain 
decrease in the number of conjugates formed by SDC-4 Jurkat T cells and Raji B cells pre-
loaded with the superantigen. Nevertheless, the technique was extremely sensitive to the 
experimental conditions, such as the sample temperature throughout all steps of the 
preparation.  
 
Later, live cell imaging was applied for more advanced analysis of T cell conjugation with 
antigen-bearing APCs. The advantage of this technique is that one can ‗see‘ all steps of the 
interaction between the cells and observe the conjugates over a longer period of time (section 
Live cell imaging) to investigate their stability and morphology. The results achieved using live 
cell imaging of transfected Jurkat T cells and Raji B cells indicate that Jurkat T cells 
overexpressing SDC-4 form conjugates slightly less frequently than those transfected with 
EGFP but there is no significant difference in the overall numbers of formed conjugates. These 
data correlate with those achieved using flow cytometry and point to the fact that the global 
analysis of conjugates cannot uncover differences in the IS formation in the presence or 
absence of the increased SDC-4 expression. 
 
Such differences were well observable by eye and I therefore decided to take advantage of 
single cell image data analysis of individual cell morphology which may influence T cells 
activation [108]. A dissimilarity was confirmed in shapes of Jurkat T cells transfected with    
SDC-4-encoding plasmid but forming conjugates with Raji B cells and those transfected with 
EGFP-only plasmid. Due to the time constraints I was unable to find the optimal way of the 
shape analysis yet, but factors such as asymmetry, roundness and relative border of T cell to B 
cell well document my visual observations. The data indicate that the engulfment of Raji B cells 
by SDC-4 overexpressing Jurkat T cells is smaller than Jurkat T cells expressing only EGFP. 
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Also, the contact site between conjugating cells is much smaller for proteoglycan-expressing 
Jurkat T cells than for controls. 
 
The downside of the live cell imaging mentioned above is that the images taken during the first 
2-3 minutes of the conjugates formation are ‗disturbed‘ by the landing cells and the detection 
(image data analysis) of cells is more difficult. I observed reduced formation of conjugates by 
Jurkat T cells overexpressing SDC-4 compared to those expressing EGFP only. Keeping in 
mind the abovementioned drawback of live cell imaging I tested the signalling in conjugating 
Jurkat T cells using Western blotting. I observed significant delay in the signalling events (herein 
represented by phosphorylation of effector proteins on tyrosine) in SDC-4 overexpressing Jurkat 
T cells compared to those expressing EGFP only. The data were also confirmed using flow 
cytometry to detect the signal for individual cells. 
 
4.2 Discussion and future perspectives 
T lymphocyte activation is regulated by stimulatory and inhibitory signals transduced 
simultaneously or after the binding of TCR to its corresponding ligands on APCs [97, 147, 150]. 
Stimulatory receptors tend to be present constitutively on the surface of resting T cells, whereas 
inhibitory receptors require activation for their expression or localisation to the IS [175]. 
Syndecans, similar to other accessory molecules, can contribute positively or negatively to the 
antigenic stimulation of T cells by antigen. Recent results indicate an inhibitory role for SDC-4 in 
human and mouse T cells [143, 150]. The novel ligand for SDC-4 (DC-HIL expressed by human 
monocytes and dendritic cells) promoted its inhibitory function [143, 149], but published results 
did not analyse the effect of SDC-4 on T cell morphology and early activation events. Ariizumi et 
al noticed negative effect on distal signalling effects (such as IL-2 production)[143], but I did not 
observe any overall dramatic effect of SDC-4 overexpression on proximal signalling in Jurkat T 
cells. The only detectable difference was the delay in signalling. Also, I am not aware of DC-HIL 
expression in B cells, so I do not expect the effect of this interaction on the morphology of T 
cells described in my work but this needs to be tested. I decided to investigate the impact of 
SDC-4 on IS formation. First, I did not manage to prove a systematic global effect, such as 
complete block of the IS formation, but the shape changes indicate that SDC-4 influences the IS 
formation or, at least, adhesive forces involved in these morphological changes.  
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The fact is that syndecans cannot be considered in isolation for any system studied. For 
example, syndecans and integrins collaborate extensively in mediating cell adhesion [1] to a 
broad range of ECM molecules and can combine synergistically to regulate FA-complex 
formation [176], cell spreading and directional migration [19, 65]. In addition, some growth 
factors and their high-affinity receptors can influence cell-matrix relationship based on the 
modulation of syndecan-integrin network [4, 32].  
Given the propensity of the syndecans to homodimerise and multimerise [45] in response to 
ligand engagement [148], it seems likely that the SDC-4 extracellular domain might regulate the 
assembly of other multi-molecular cell surface signalling or adhesion complexes because of 
GAG chains presence [21]. Looking from the T cell side, molecular structures and biochemical 
events involved in T cell activation are taking place in the supramolecular structures formed at 
the plasma membrane and have been increasingly well-described [76]. Nevertheless, scientists 
using biophysical and imaging approaches naturally tend to focus on the events directly related 
to the TCR engagement and proximal signalling using simplified experimental approaches, such 
as stimulatory supported planar bilayers containing just two ligands (pMHC and ICAM-1) or 
antibody stimulation [73, 105]. Such approaches may miss the complex character of T cell 
activation, in which molecules such as SDC-4 may play a regulatory role. My observations 
expand the knowledge on the factors regulating T cell morphology and adhesion during its 
activation. 
Recent publications of Ariizumi group [177] indicates that because SDC-4, as mentioned before 
the coinhibitor for DC-HIL, lacks immunoreceptor tyrosine- based inhibitory motifs (ITIMs), 
through which most coinhibitory receptors regulate T-cell responses that recruits protein tyrosine 
phosphatases to mediate inhibitory function. Therefore, they posited that SDC-4 links with a 
protein tyrosine phosphatases in an ITIM-independent manner. They showed  that SDC-4 
associates constitutively with the intracellular protein syntenin [50], but not with the receptor-like 
protein tyrosine phosphatase  CD148 on human CD4+ T cells. Binding to DC-HIL allowed SDC-
4 to assemble with CD148 through the help of syntenin as a bridge, and this process 
upregulated the activity of CD148, which is required for SDC-4 to mediate DC-HIL's inhibitory 
function [177]. It may also explain my observation, that there is no colocalisation of SDC-4 with 
TCRs, as SDC-4 may be excluded from the IS and be accumulated there at the resolution point, 
when inhibitory molecules like CD148 are brought [178]. 
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In summary, SDC-4 is a complex molecule, is highly expressed only in activated T cells, and its 
interactions with other ligands (e.g. DC-HIL) influence T cell activation (as shown by Ariizumi 
group) [141, 143, 177]. Its overexpression in T cells also influences the IS formation (presented 
in my thesis). I have not been able to describe the detailed mechanism behind the effect of 
SDC-4 on T cell conjugation with APCs.  
Therefore, there are still numerous issues regarding SDC-4 and T cells to study. My results 
showing the shape differences between Jurkat T cells transfected with pHA-hSDC-4-IRES-
EGFP and pIRES-EGFP plasmids which form conjugates with Raji B cells (APCs) (loaded with 
SEE) suggest limited contact between these cells - less engulfment of Raji B cell by the T cell. 
Such impact may have consequences in delayed search for pMHC because of the presence of 
big GAGs attached [63] , or, in later phases to reduce the contact and help the detachment of T 
cell from the APC. I was actually able to observe delayed proximal signalling in my model 
system. 
 
Due to time constraints I was unable to perform all experiments one would think of after seeing 
the impact of SDC-4 on the morphology of IS. For example, it would be interesting to test the 
effect on the IS formation using SDC-4 lacking HS chains (e.g. by applying heparinise  for their 
removal, or the use of a mutated - unglycosylated – gene of SDC-4 for the transfection ). In 
addition, my results indicate some effect of SDC-4 on early signalling events. SDC-4 can 
stabilize and activate the activity of PKC-α [61, 171] with possible influence of TCRs function. 
Therefore, in future, these data should be expanded in a more detailed study using a variety of 
phospho-specific Abs to get more precise information on which specific signals have been 
delayed or whether the initiation of TCR signalling on its own was affected. 
Actin cytoskeleton is a driving force of the attachment to and engufment of T cells on APC [179]. 
From the studies performed using motile fibroblast, it is also known that SDC-4 can influence 
actin cytoskeleton [62, 173]. Therefore, the possible explanation of my observation regarding 
shape changes in Jurkat T cells during conjugates formation may be due to the SDC-4 
regulatory role for the actin cytoskeleton [62]. It would be interesting to check the actin and 
SDC-4 co-localisation and the impact on actin-driven forces using our model system. Indeed, in 
collaboration with the group of Robert Endres (CISBIC, Imperial College London) we are 
analysing our live cell imaging data with respect to the forces generated during the conjugates 
formation. 
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It may be possible that SDC-4 present on the surface, but not interacting with fibronectin and 
generating the ECM-driven signal, can influence the adhesion between two interacting cells 
[62]. There is possibility that SDC-4, in this way, interacts with integrins on the membrane of the 
same cell in cis  (e.g. the plasma membrane of T cell in our case), and modulates intracellular 
events such as integrin-actin bundling and cytoskeletal changes normally stimulated by cell-to-
cell adhesion [1]. Such interaction can make the conjugate formation more difficult, especially 
during stages of the contact. Thus, it would be interesting to investigate the localisation of 
integrins (not just LFA-1) in the IS and their co-localisation with SDC-4, as well as the effect of 
the SDC-4 over-expression on their function. 
 
It is important to note that all my results were achieved using CD4+ T cells or the model Jurkat 
T cells (mimicking early stage of CD4+ T cell development) and cannot be simply implicated for 
cytotoxic (CD8+) T cells without further testing. Also, no other SDCs have been described in T 
cells so far.  
Although SDC-4 was initially identified as a co-receptor of integrins, its expression in other 
tissues, including T cells, implies a more widespread role. Results from studies in T cells 
suggest that SDC-4 function is linked to TCR signalling and cell activation. Despite these initial 
findings, there are big gaps in our knowledge regarding the function of SDC-4 in T cells and the 
immune system in general, at both the molecular level and at the level of the whole organism. At 
the molecular level important areas of investigation, although by no means the only ones, are: to 
understand the nature of SDC-4 modification induced early on during T cell activation; to 
explore the role of SDC-4 in cell-cell adhesion during antigen presentation; and to identify the 
receptor(s) that mediate the effects of SDC-4 in immune cells. At the organism level, vital 
information will be generated by: studying how T cells and the immune system in general 
develop in the absence of SDC-4 expression; assessing changes in immune responses of 
viable SDC-4-/- mice compared to wild type; and studying whether higher expression of SDC-4 
in T cells in engineered mice predisposes to T cell hyperactivity and autoimmunity. Many tools 
are already available to study the biology of SDC-4 and we anticipate that these issues will be 
addressed in the near future by immunologists with different areas of expertise. These studies 
may well prove that SDC-4 has a critical role in the immune system. 
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